Protein tyrosine kinase

ABSTRACT

The present invention is directed to a novel protein tyrosine kinase comprising a polypeptide having multiple protein kinase catalytic domains and, more particularly, two kinase catalytic domains and to genetic sequences encoding same. Two such kinases are described and designated JAK1 and JAK2.

The present invention relates generally to a novel protein tyrosine kinase and to genetic sequences encoding same.

Protein tyrosine kinases (PTKs) are structurally well suited to a role introcellular signal transduction. Many growth factor receptors, for example, transduce the extracellular stimulus they receive through interaction with their cognate ligand via an intracellular tyrosine kinase domain. At least one of the non-receptor PTKs, namely LCK, is believed to mediate the transduction in T-cells of a signal from the interaction of a cell-surface protein (CD4) with a cross-linked anti-CD4 antibody.

The broader family of PTKs can be sub-divided on the basis of structural parameters of individual members. For example, the src family of PTKs now numbers 8 members (Marth et al., 1985; Nishizawa et al. 1986; Semba et al., 1986; Martinez et al., 1987; Sukegawa et al., 1987; Yamanishi et al., 1987; Hotzman et al., 1987; Dymecki et al., 1990), each with a characteristic complement of extra-catalytic domains, including an SH2, an SH3 domain and a variable ligand binding domain. It is clear that a process of gene duplication has taken place in this case, so that the evolutionarily successful thematic structure of this family can be employed in a variety of cellular contexts. Similarly PTK structural sub-families exist based around the PGF receptor and the CSF-1 receptor (reviewed in Wilks, 1990).

However, one feature in common with the aforementioned PTKs is that each kinase bears a single highly related "catalytic" domain.

In accordance with the present invention a protein tyrosine kinase is provided which is distinct from those previously known, in particular, the protein tyrosine kinase of the present invention is unique since it possesses more than one protein kinase catalytic domain. Furthermore, the kinase does not bear an SH2 domain. The novel protein tyrosine kinase of present invention represents a new subfamily or class of protein tyrosine kinase.

Accordingly, one aspect of the present invention is directed to an animal protein tyrosine kinase-like molecule comprising a polypeptide having multiple protein kinase catalytic domains but no SH2 domain.

Preferably, the polypeptide has two protein kinase catalytic domains.

Preferably, the animal is a mammal and is most preferably a human or a mouse.

Hereinafter, a protein having these characteristics will be referred to as a "JAK" (from JAnus Kinase: Janus, in Encyclopacdia Britannica (11Th Ed) Vol XV pp 155-156). The present invention is specifically exemplified using JAK1 and JAK2 from humans and mice. This is done, however, with the understanding that the present invention extends to the whole family of JAKs from all animals and to mutants, derivatives, analogues and homologues thereof. The term "protein tyrosine kinase-like molecule" (abbreviated herein to "PTK-like molecule") is used throughout the specification and claims to emphasise that the present invention encompasses all members of the JAK family and to their mutants, derivatives, analogues and homologues.

In accordance with the present invention, there is provided a PTK-like molecule. Preferably the molecule is in biological pure or in substantially pure and/or synthetic form. The purity of the preparation is characterized by a sample comprising at least 70% by weight, preferably at least 80% by weight and most preferably at least 90% by weight PTK-like molecule. Alternatively, where the purity of the enzyme preparation is not critical, the present invention also encompasses an impure PTK-like molecule preparation but which possesses a substantial amount of JAK activity.

The present invention is directed to a naturally occurring PTK-like molecule, biologically pure or substantially pure as hereinbefore defined and to derivatives, functional analogues and homologues thereof. Such derivatives include polypeptides having single or multiple amino acid substitutions, deletions and/or additions relative to the naturally occurring sequence. These derivatives, functional analogues and homologues also encompass single or multiple substitutions, deletions and/or additions to any associated molecules such a carbohydrate, lipid and/or proteinacious moieties. Reference herein to "PTK-like molecules" includes all such derivatives, functional analogues and homologues. The present invention also extends to synthetic forms of the polypeptides which include recombinant molecules and molecules prepared by the stepwise addition of amino acids to groups of amino acids in defined order.

A range of derivatives and analogues of the PTK-like molecule are contemplated herein and include altering the molecule at its nucleotide sequence-encoding level, during its expression within a cell or in vitro or post-synthesis modification. Such derivatives and analogues include, but are not limited to, modifications to side chains, incorporation of unnatural amino acids during polypeptide synthesis and the use of crosslinkers and other methods which impose conformational constraints on the polypeptide or their analogues.

Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBII₄ ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6, trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5'-phosphate followed by reduction with NaBH₄.

The guanidino group of arginic residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

The carboxyl group may be modified by carbodiimide, activation via O-acylisourca formation followed by subsequent derivatisation, for example, to a corresponding amide.

Sulphydryl groups may be modified by methods such as carboxymethylation with iodioacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercurlbenzoate, 4-chloromercurlphenylsulphonic acid, phenylmercury chloride, 2-chloromercurl-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

Modification of the imidazole rings of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

Examples of incorporating unnatural amino acids and derivatives during polypeptide synthesis include, but are not limited to, use of norleucine-4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, G aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3 hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids.

Crosslinkers can be used, for example, to stabilise 3D conformations, using homo-bifunctinoal crosslinkers such as the bifunctional imido esters having (CH₂)_(n) space groups with n=1 to n=6, glutaraldehyde, N hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, polypeptides could be conformationally constrained by, for example, incorporation of C_(a) N_(a) -methylamino acids, introduction of double bonds between C_(a) and C_(B) atoms of amino acids and the formation of cyclic polypeptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.

The present invention, therefore, extends to peptides or polypeptides and amino acid and/or chemical analogues thereof corresponding to regions of PTK-like molecules. Preferably, the PTK-like molecules will retain JAK activity. However, molecules carrying mutations in the catalytic domains rendering these inactive may be useful in, for example, titrating out activity and generation of antibodies such molecules are encompassed by the present invention.

The molecular weights of the PTK-like molecules of the present invention range from 100,000 to 200,000 daltons and preferably from 120,000 to 150,000 daltons.

In a most preferred embodiment, the present inventions provides JAK1 and JAK2. JAK1 is an approximately 1142 amino acid molecule with a molecular weight of about 132,000 daltons and a nucleotide sequence shown in FIG. 2, JAK2 is an approximately 1,000 amino acid molecule with a molecular weight of about 130,000 daltons and with a nucleotide sequence shown in FIG. 8.

The present invention is also directed to genetic sequences including DNA, cDNA and mRNA which encode the PTK-like molecules hereindescribed. Such genetic sequences include single or multiple nucleotide substitutions, deletions and/or additions relative the naturally occurring sequence and extend to sequences encoding the derivatives, functional analogues and homologues of the PTK-like molecules. The present invention also provides these genetic sequences in vector and expression vector systems either in vitro or in a biological system (i.e. eukaryotic or prokaryotic cells) transformed with such vectors or genetic sequences. In a most preferred embodiment the present invention provides cDNA encoding JAK1 and JAK2 as set forth in FIGS. 2 and 8, respectively. A range of mutants can be obtained using standard techniques such as an oligonucleotide mutagenesis and chemical mutagenesis, and all such mutants and derivatives are encompassed by the present invention.

The present invention also provides antibodies to a PTK-like molecule. Such antibodies may be monoclonal or polyclonal.

The PTK-like molecule of the present invention have varying utility such as in the phosphorylation of proteins, incorporation of labels and in the design of analogues, antagonist and agonists of JAKs.

Accordingly, another aspect of the present invention contemplates a method for phosphorlyating a protein comprising containing said protein with a phosphorylating effective amount of a PTK-like molecule, said molecule comprising a polypeptide having a multiple protein kinase catalytic domains but no SH2 domain for a time and under conditions sufficient for said first protein to be phosphorylated. Preferably, the polypeptide has two protein kinase catalytic domains and most preferably is JAK1 and/or JAK2 and/or their derivatives.

The present invention is further described by reference to the following non-limiting Figures and Examples.

In the Figures:

FIGS. 1A and 1B are a photographic representation of a Northern analysis of murine and human JAK1.

FIG. 1A. 2 μg aliquots of poly(A)+ mRNA from murine tissues: lane 1, lung: lane 2, liver; lane 3, kidney; lane 4, intestine; lane 5, brain; lane 6, skeletal muscle; lane 7, spleen; lane 8, slivary gland; lane 9, placenta; lane 10, mammary gland, were fractionated on a 1.0% agarose/formaldehyde (Moran et al. 1988) gel and the RNA transferred onto a Genescreen plus (Dupont) membrane. The transferred RNA was hybridized with a 1.8 kb ³² P-labelled murine JAK1 probe and the filter autoradiographed for 16 hr. at -70° C. with two intensifying screens. The relative mobilities of 28S rRNA (upper arrow) and 18S rRNA (lower arrow) are shown.

FIG. 1B. 2 μg aliquots of poly(A)+ mRNA from the human haemopoictic cell lines; lane 1, IIL60 (myelo-monocytic); lane 2, U937 (monocytic): lane 3, LK63 (pre-B): lane 4, RAJI (B-cell): lane 5, CEM (T-cell): lane 6, K562 (erythroleuknemia) were fractionated on a 1.0% agarose/formaldehyde (Moran et al., 1988) gel and the RNA transferred onto a Genescreen plus (Dupont) membrane. The transferred RNA was hybridized with a full-length ³² P-labelled human JAK1 probe and the filter autoradiographed for 16 hr. at -70° C. with two intensifying screens. The relative mobilities of 28S rRNA (upper arrow) and 18S rRNA (lower arrow) are shown.

FIG. 2 is a representation showing nucleotide sequence and predicted amino acid sequence of human JAK1. The DNA sequence is numbered at the end of each line of sequences from the first nucleotide of the largest clone (pTIJ7.3), the amino acid sequence (in one letter code) is numbered from the putative AUG and appears above the line to which it refers. The two kinase catalytic domains are boxed with arrows, and kinase consensus motifs are enumerated according to the nomenclature of Hanks et al (1988). The suffix a (e.g. IIa) denotes the kinase related motifs present in the first kinase related domain (designated domain-1 in FIG. 3a) also numbered according to the same nomenclature. The tyrosine residue in an analogous position to the autophosphorylation site of a number of other protein tyrosine kinases is marked with an inverted triangle.

FIGS. 3A and 3B are a representation showing:

FIG 3A. Amino-acid sequence comparison of the two kinase-related domains of JAK1. The amino-acid sequences (expressed in one-letter amino acid code) of the two kinase-related domains (domain-1 amino-acids 576-825; domain-2 (PTK-domain) amino-acids 868-1139) of JAK1 and the human threonine/serine-specific kinase CDC2 (24) (amino acids 9-272) are aligned in order to maximize identity. The kinase-related domains have been divided into three segments and the number of amino acid residues separating each segment appears at the end of each line. Motifs held in common between at least two of these domains are both bolded and boxed. Roman numerals above the alignment correspond to the conserved domain nomenclature devised by Hanks et al (1988).

FIG. 3B Hydropathy plot of the human JAK1 protein. The protein sequence of human JAK1 (including the 10 extra amino acids which precede the most likely initiation codon) were analysed by the hydrophilicity algorithm of Kyte and Doolittle (1982) using a span length of 25 amino acids. The relative locations of the two kinase related domains are marked as Domain-1 and PTK. The absence of a hydrophobic transmembrance domain is clearly seen, as can the presence of a highly hydrophilic region between amino acids 323 and 350.

FIGS. 4A-4C are a representation of an analysis of the JAC1 protein.

FIG. 4A. Cellular proteins of the murine mammary fibroblast cell line (17) were labelled with ³⁵ S-methionine (panel A) and immunoprecipitated with either pre-immune (PI) or immune (I) anti-JAK rabbit antiserum (raised in rabbit M8 against the pGEX/JAK1/1 fusion protein or the C-terminal peptide M3!) and fractionated on a 9.5% SDS-PAGE gel (Laemmil, 1970). Both rabbit antisera specifically immunoprecipitated an ³⁵ S-labelled protein of apparent of apparent molecular weight 130,000D.

FIG. 4B. Demonstration of tyrosine kinase activity in JAK1 bacterial fusion proteins. JAK1 fusion proteins were generated using pGEX2 (Smith and Johnson, 1988). The entire domain-1 region was included in construct pGEX/JAX1/1. The PTK domain portion of the fusion protein extended to the BamHI site 15 nucleoides 5' of the first glycine codon of the GXGXXG motif (SEQ ID. No: 3) of the ATP binding site. An empty vector control was also performed. The bacteria were induced by the addition of 1 mM. IPTG as described by Smith and Johnson (1988) and two 1 ml aliquots of the bacteria were removed at 60 minutes and 120 minutes post-induction and lysed with SDS sample buffer. Western analysis of the samples was performed using anti-phosphotyrosine antisera (PY-20 ICN!). The arrow heads mark the positions of the GEX-JAK fusion proteins, in each induction.

FIG. 4C. Construction of the pGEX/JAK fusion proteins. The locations of the two kinase related demains of JAK1 are shown, and below, the structure of the fusion proteins with the glutathione S. transferase gene.

FIG. 5 is a representation of a sequence comparison between JAK1 and JAK2 kinase-related domains. The deduced amino acid sequence of murine JAK2 was compared to the human JAK1 amino acid sequence by application of an alignment programme of the Staden VAX-based suite of Sequence analysis programmes. Asterisks (*) denote identity, dollar signs ($) denote conservative substitutions. Sequences are numbered with respect to the JAK1 sequence. The extent of the domain-1 are PTK domains is shown by arrows above the amino acid sequence.

FIG. 6 is a graphical representation of a phylogenetic analysis of the two JAK1 Kinase-like domains. The tree building concept of Fitch and Margoliash (1967) as implemented by Feng and Doolittle (1987) and Hanks et al. (1988) was used to generate a phylogenetic tree as described in Example 1. In each case the catalytic domain alone was used for comparison. The two kinase related domains of the JAK1 protein were compared independently. Branch order is a function of structural similarity, branch length a function of sequence identity. The abbreviations used are: SRC=c-scr; YES=c-Yes; FES=c-fes; CSF1-R=Colony stimulating factor-1 receptor; KIT=c-kit; PDGF-R=Platelet derived growth factor receptor-A; RET=c-RET; ANP-A=Atrial naturetic peptide receptor-A; ANP-B=Atrial naturetic peptide receptor-B; MOS=c-mos; PBS2=polyxinn B antibiotic resistance gene product; STE7=sterile mutant wild-type allele gene product; JAK1/1=Domain-1 of Human JAK1; JAK1/2=PTK domain of Human JAK1.

FIG. 7 is a diagramatic representation showing models for the rule of members of the JAK family of PTKs in signal transduction. Two possible scenarios are considered based on an extrapolation of the current notions of the role of PTKs in signal transduction. In panel A the N-terminal domain of the JAK protein serves to sense a particular metabolic cue and convert this input into two distinct outputs. Presumably the output of the second PTK-related domain is tyrosine kinase activity; the activity of Domain-1 remains unknown. In panel B an alternative scenario is considered. In this case the function of Domain-1 is the regulation of the PTK domain. In this scenario the sole output of the JAK protein is the PTK activity.

FIGS. 8A and 8B are a representation of a nucleotide sequence and predicted amino acid sequence of murine JAK2. The nucleotide sequence is numbered beneath each line of sequence, from the first nucleotide of the most 5' clone. The predicted amino acid sequence, in one letter code, is numbered at the end of each line of sequence. The two putative kinase domains are shown boxed with arrows, and the kinase consensus motifs are enumerated according to the nomenclature of Hanks et al (1988). The subscript a denotes the kinase-related motifs present in the first kinase-related domain, which are numbered according to the same nomenclature.

FIG. 9 is a photographic representation showing expression of JAK2 in murine tissues. Northern blot analysis of 5 μg of mRNA from each of the tissues shown on top of the figure and from various murine (30F: mammary fibroblasts; 31A: mammary epithelial cells; 30.1; factor independent subline of the hemopoietic cell line FDC.Pl; N1H: fibroblasts) and human (K562; chronic myclogenous leukaemic cells) cell line. The blots were hybridized with a ³² P-labelled 2.2 kb JAK2 probe and autoradiographed was for 4 days. The relative mobilities of the 28S and the 18S rRNA are indicated.

FIG. 10 is a graphical representation showing comparison of JAK1 and TYK2 amino acid sequences. The amino acid sequences of JAK1 (Wilks et al, 1991) and TYK2 (Firmback-Kraft et al, 1990) were compared using the HOMOLOGY option in the programme SEQMATCH, using a window length of 21 amino acids. The ordinate of the graph represents the percentage identity between the two sequences, the abscissa represents the amino acid position in JAK1 at which the particular level of identity was calculated. The shaded boxes below the graph represent arbitrarily ascribed JAK homology domains as discussed in the test and further demonstrated in FIG. 11.

FIG. 11 is a representation showing amino acid sequence comparison of members of the JAK family of PTKs. The aminoacid sequences of JAK1 (Wilks et al, 1991) (designated J1 in this figure), JAK2 (J2 in this figure), and TYK2 (Firmback-Kraft et al., 1990) (T2 in this figure) were aligned using the CLUSTAL program (Higgins and Sharp, 1988). The numbering system is relative only to the first amino acid of JAK1, and does not take into account the insertion of gaps into this sequence; it is therefore useful only as a relative measure of location. The extent of each of the JAK homology domains was determined with reference to the homology plot shown in FIG. 10. Amino acid positions conserved in at least 2 our the 3 sequences presented are bolded and presented below the TYK2 sequence as a consensus sequence.

FIG. 12 is a representation showing a comparison of the JH3/JH4 domain region with SH2 domains. The two SH2 domains of GAP (the more N-terminal domain denominated GAP-N (residues 178-269), the more C-terminal, GAP-C, (residues 348-438) (Trahey et al, 1988), and the SH2 domain of work (residues 248-354) (Mayer et al, 1988) were compared with the JH3/JH4 of JAK1 (residues 425-536) (Wilks et al, 1991), JAK2 (residues 252-359) (this manuscript) and TYK2 (residues 449-555) (Firmback-Kraft et al, 1990). Amino acids held in common between the two classes of sequence are denoted by vertical lines between the two sets of sequences. Conserved residues held in common by members of the same class of domain are bolded.

EXAMPLE 1 Materials and Methods

Screening of cDNA libraries

Several cDNA libraries were screened according to the protocols outlined in Maniatis et al, (1982). cDNA libraries from Murine NFS TPA activated spleen (Clontech cat. #ML1018), murine swiss-albino 3T3 fibroblast (Clontech cat.#1023b), murine balb/c bone marrow (Blontech cat.#ML1007), murine swiss-webster whole brain (Blontech cat.#ML1002), murine ICR linoleic acid activated pleural macrophage (Clontech cat.#ML1005b), and human 1st-trimaster foetal liver (Clontech cat.#HL1005b) were all generated in λgt 11. cDNA libraries from murine Balb/c testis (Clontech cat.#ML1020b), murine day 10 embryonic neuro-epithellum (Reid et al, 1990) and human foreskin fibroblast cell line AG1518 (Claesson-Welsh et al, 1989) were generated in λgt10. Around 10⁶ recombinants of each of these libraries were screened on each occasion.

Library screening was carried out as follows. The FD22 (JAK1) PCR clone was labelled by nick-translation (Maniatis et al, 1982) and used to screen the murine libraries. A murine cDNA clone of 1.8 kb was isolated amongst 3 other positives from the neuro-epithelial and bone marrow cDNA libraries. Two full-length human JAK1 cDNA clones were isolated from the unamplified human foreskin fibroblast cell-line AG1518 by using the murine cDNA as a probe. Hybridisation was at 65° C. in 6xSSC; 1% SDS; 0.5% Blotto; 200 μg/ml sonicated and denatured herring sperm DNA. After hybridisation, the stringency of the final wash was 0.2xSSC; 0.1% SDS at 65° C. Filters were autoradiographed overnight using Kodak XAR-5 X-ray film.

For JAK2, the murine macrophage was screened first with the FD 17 (JAK2) PCR clone, Yielding 5 positives, and a portion of the longest cDNA clone isolated and used to screen the remaining cDNA libraries. Hybridisation conditions were as above for JAK1.

DNA sequencing

Two strategies were employed for the sequencing of JAK1 and JAK2 cDNA clones. In the case of the human JAK1 sequence, the Erase-a-Base kit (PROMEGA) was employed to generate nested deletions of the largest EcoRI fragment. All of the murine JAK2 sequence data, and the remainder of the human JAK1 sequence, was determined using oligonucleotide primers based on previously determined DNA sequence. In each case the sequence information was generated using the dideoxynucleotide chain termination method (Sanger et al, 1977). All sequence information was determined on both strands.

Northern Analysis

Poly A+ mRNA samples were prepared as elsewhere described elsewhere (Wilks and Kurbon, 1988). Aliquots (1 μg) were analysed by electrophoresis on a 1% agarose gel containing 2.2M formaldehyde; 20 ml MOPS, pH 6.8; 1 mM EDTA; 5 mM sodium acetate, and transferred to Hybond (Amersham, cat #RPN303N) or nitrocellulose (Schleicher & Schuell, HA85, cat #401196) membranes. Filters were prehybridised for 4 hr in 50% formamide containing 3xSSC, 5xDenhardts; 10 mM HEPES pH 7.0; 100 μg. ml 1; poly C; 100 μg/ml denatured herring sperm DNA; 10 μg/ml E. coli DNA; 0.1% SDS, and hybridised in the same solution with nick-traslated ³² P-labelled murine or human JAK1 or JAK2 insert, for 18 hr. at 42° C. Filters were washed to a final stringency of 0.2xSSC; 0.1% SDS at 65° C., before exposure to Kodak XAR-5 X-ray film, with two intensifying screens.

Antibody Reagents and Protein Analysis

Polyclonal rabbit antisera M7 and M8 were raised against affinity purified pGEX/JAK1/1 bacterial fusion protein (see section on kinase assays). Polyclonal antibodies M3 and M4 against the C-terminal peptide (-TSFQNLIECFEALLKC-) (SEQ ID No:4) of JAK1 were raised in rabbits. Peptide was coupled in Keyhole Limpet Heamocyanin with 0.05% gluteraldehyde, emulsified in Frends' complete adjuvant and injected intradermally at several sites. The animals were boosted four and seven weeks later with coupled peptide emulsified in Freunds' incomplete adjuvant and bled ten days after the last injection.

Cells were metabolically labelled with either ³⁵ S-methionine or ³² P-orthophosphate in methionine- or phosphate-free medium containing 100 μCi/ml and 1 mCi/ml isotope respectively. RIPA-buffer (20 mM Tris, pH7.5 containing 1% Triton X100, 1% Na deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM PMSF) extracts were incubated on ice with antiserum and immune-complexes isolated using Protein A bearing Staphylococus aureus bacteria. Proteins were resolved by SDS-PAGE (Laemmli, 1970) and radioactively labelled bands detected by exposure to X-ray film (Kodak XAR-5). The RPTA buffer for ²³ P-labelled calls contained in addition 20 mM EDTA, 10 mM NaF, 100 μM orthovanedate as phosphatase inhibitors.

Phosphoamino-acid analysis of excised ³² P-labelled bands was carried out exactly as described by Hunter and Sefton (1980) Western blot analysis was performed as described by Towbin et al. (1979) as modified in Ziemiecki et al (1990) using either alkaline phosphatase or ¹²⁵ l-labelled protein-A as a detection system.

Protein Kinase Assays

A variety of protocols have been tried in order to reveal the PTK activity of the JAK1 protein. First, extraction of murine mammary fibroblasts, Reichmann et al (1989) has been performed in a range of buffers, containing Triton-X100 or Nonidet P40 (1.0%) alone, or with added Sodium Deoxycholate (0.5% or 1.0%) or in RIPA buffer (containing 1.0% Triton-X100; 1.0% Sodium Deoxycholate; 0.1% Sodium Dodecylsulphate). Cells have been extracted in the presence or absence of phosphates inhibitors, such as 20 mM EDTA, 10 mM NaF and 100 μM Na2V04.

After immunoprecipitation, kinase assays have been performed in a range of ATP concentrations (100 nM-10 mM) or with carrier-free γ-35P-ATP (Amersham cat #10169) in either 20 mM Tris, pH 7.4 or 50 mMM HEPES PII 7.4, with either 10 mM Mn⁺⁺, Mg⁺⁺ or Zn⁺⁺ as divalent cation. Incubations have been performed on ice (15 min), at 250° C. (15 min), at 30° C. (15 min) or at 37° C. (2 min) in the presence or absence of the phosphatase inhibitor Na2V04. Finally, γ-32P-GTP was employed as phosphate donor in lieu or γ-32P-ATP, with no success.

In order to generate the JAK1glutathione transferase fusion proteins shown in FIG. 4, domain-1 (from nucleotides 1770-2672 in FIG. 2) and the PTK domain (from nucleotides 2672-end in FIG. 2, thus including 5 extra amino acids beyond the ATP binding glycine motif) were each fused into the BamHI site of pGEX2. The fusion protein was induced by the addition of 1 mM IPTG as described elsewhere (Smith and Johnson, 1983) and Western blot analysis performed on an induction time course with the M3 anti-JAK1 serum, and the anti-phosphotyrosine antiserum (Kamps and Sefton, 1988). Several sources of anti-phosphotyrosine antisera were tried. The data in FIG. 4b were obtained using a commercially available monoclonal antibody preparation PY-20 (ICN). In control experiments, induction of the insert-less pGEX or pGEX/JAK1 fusion protein produced no detectable tyrosine phosphorylation of bacterial substrates and the reactivity of the anti-phosphotyrosine antiserum could be completely abolished by the additional of phenyl phosphate.

Computer Aided Sequence Analysis

Amino acid sequence comparisons were performed using an alignment programme from the Staden-based suite of programmes on a VAX VMS 5.2. The phylogenetic analysis of the two kinase-like domains of JAK1 was performed using the tree-building concept of Fitch and Margoliash (1967) as implemented by Feng and Doolittle (1987). The SCORE programme used to construct the difference matrices from which the trees were derived using the BORD AND BLEN programmes, were all the gift of Dr. R Doolittle of the University of California--San Diego.

The sequence alignment shown in FIG. 11 was assembled using the CLUSTRAL program (Higgins and Sharp, 1988) on a VAX VMS 5.2 minocomputer. The homology plot shown in FIG. 10 was assembled using the HOMOLOGY option of the programme SEQMATCH. Database searches with each of the JAK homology domains was reformed using the PASTA programme, based on the Pearson/Lippman algorithm (Pearson and Lippman, 1988).

Rack/Anchor PCK

RACE/Anchor PCR (Frohman et al., 1990; Loh et al., 1990) was performed by a modification of the original protocol. Briefly, 2 μg of poly(A+) mRNA is converted to cDNA using an Amersham cDNA synthesis kit (cat No. RPN 1256) and 40 ng. of a JAK2 specific oligonucleotide primer (5' TACACCTTTAAATATTTTTGT-B') (SEQ ID. No: 5). Prior to the addition of the reverse transcriptase, the reaction mixture was heated to 65° C. cDNA synthesis was initiated by the addition of 20 units of reverse transcriptase, and the reaction incubated at 55° C. for 75 minutes. The newly sunthesised cDNA was recovered by passage through a spun sephadex column (Maniatis et al. 1982) followed by ethanol precipitation. The mRNA/cDNA, heteroduplex was G-Tailed in 30 μl containing 140 mM potassium cacodylate, 30 mM Tris, (pH 7.2). 1 mM CoCl₂, 0.1 mM DTT, 6 mM dGTP and 15 units of TdT (1BI), for 10 minutes at 37° C. The reaction was terminated by heating to 65° C. for 15 minutes and then diluted to 500 μl with 10 mM Tris. HCl (pH7.5). 1 mM EDTA. For the RACE/Anchor PCR, 10 μl of the tailed cDNA was reconstituted into 100 μl PCH buffer (50 mM KCl, 10 mM Tris. HCl pH8.3!, 1.5l mM MgCl₂, 0.01% gelatin, 200 μM of each dNTP) to this was added 50 mg of "poly-C" oligonucleotide primer (5'-CTCGAGTCGACGAATTC₁₄ -3') (SEQ ID No: 6) and 2.5 units of TAQ polymerase (Cetus). the complementary strand of the cDNA was synthesised with one cycle of 95° C. (5 minutes), 52° C. (5 minutes) and 68° C. (40 minutes), whereupon 500 μg of the "RACE/Anchor" primer (5'-CTCGAGTCGACGAATTC-3') (SEQ ID. No: 7) and a nested JAK2 specific primer (5'-CTTGCTTAATACTGACATCA-3) (SEQ ID. No: 8) were added and the reaction mix subjected to 30 cycles of 95° C. (1 minute), 52° C. (2 minutes) and 68° C. (5 minutes). The PCR product was phenol/chloroform extracted, precipitated and resuspended in 100 μl of water. The amplified material was then kinased, size fractionated on a low-melting temperature agarose gel and cloned into SmaI cleaved M13mp8. Plaques were screened by hybridisation with a JAK2 cDNA, and positives sequenced.

EXAMPLE 2 Isolation and DNA sequencing of cDNA clones encoding JAK1

JAK1 cDNA was cloned using PCR. Northern analysis (FIG. 1a and b) demonstrated that in both mouse and human tissues and cell lines FD22 (JAK1) was encoded by a single widely expressed 5.4 kb mRNA. Human cDNA clones of FD22 (JAK1) were isolated from a human foreskin fibroblast cell line (AG 1518) cDNA library (Claesson-Welsh et al., 1989). Two of the 8 primary isolates cloned contained inserts which were candidates for being full-length cDNAs (-5.3 kb).

The nucleotide sequence of human JAK1 is shown in FIG. 2. The 5' end of the clone has stop codons in all 3 reading frames prior to the putative initiation ATG. Two ATG start codons in frame with the longest open reading frame were found at positions 40 and 76 in the nucleotide sequence shown in FIG. 2. The first of these is embedded in a particularly poor. "Kozak" consensus sequence (Kozak, 1984) (-TAAATGCAC-) (SEQ. ID. No: 9) whereas the second matches strongly with the optimal consensus sequence defined by Kozak, namely -GCCATGGCT (SEQ. ID. No: 10). The second ATG is considered to be the initiation codon for this protein, since the first one transgresses one of the strongest correlations found in the sequences which precede initiation codons, namely the presence of a T residue (in lieu of an A residue) 3 nucleotides before the ATG sequence. At the 3' end, an in-frame stop codon at position 3502 defines the C-terminus of the protein. A large (1.405 kb) 3' untranslated region containing a polyadenylation signals completes the mRNA sequence.

The JAK1 coding region of 3426 bp encodes a protein of 1142 amino-acids with a calculated molecular mass of 132,000 daltons. The PTK catalytic domain is located towards the C-terminus of the JAK1 protein (FIG. 2). In describing the structural features of this domain we have chosen to adopt the nomenclature of Hanks et al (1988). The putative ATP binding the site composed of the motif GLY-X-GLY-X-X-GLY-Y (SEQ. ID. No: 3) (subdomain 1) followed by an invariant lysine residue (subdomain II) is located between amino acid residues 871 and 896 of the JAK1 protein. The core motifs of the PTK catalytic domain (sub-domains VI to IX) are also in their appropriate locations, and are well conserved with respect to their primary sequence and their relationship to each other. The presence of a tyrosine residue at position 1022 in the JAK1 protein, 11 residues C-terminal to sub-domain VII (a similarly placed tyrosine is a site of tyrosine autophosphorylation in v-fps; Weinmaster et al., 1984) is a consistent feature of members of the PTK family and is considered diagnostic of membership of this class of kinases. The arginine residue at position 1126 (domain XI) marks the end of the highly conserved regions of the PTK catalytic domain and the entire catalytic domain of 255 amino acids is approximately 28% (with c-fes; Wilks and Kurbon, 1988) to 37% (with TRK; Korman et al, 1988) identical to other functionally defined PTKs. Finally, there is a rare variant of the highly conserved subdomain VIII motif (residues 1032-1039), which is believed to lie close to the active site (Hanks et al, 1988). The presence of phenylalanine and tyrosine flanking the conserved tryptophan in this motif is unique to JAK1 and JAK2.

A second protein kinse-related domain (designated here Domain-1) is located between amino acids 578 and 824, 47 amino acids N-terminal to the putative PTK domain. All of the conserved elements of protein kinases are preserved spatially in this domain. In FIG. 2 these elements are numbered with respect to their similarity to the subdomains of protein kinases described by Hanks et al, (1988) (with the suffix_(a), e.g. III_(a)) and the amino acid sequences of the two kinases-related domains of JAK1 are compared to each other and to human CDC2 (Lee and Nurse, 187) in FIG. 3a. The overall structural similarity of this domain to the kinase domains of both the PTK and threonine/serine kinase families strongly suggest that this region of the protein also functions as a protein kinase. There are, however, significant differences in the sequences of key motifs within this domain which suggest that Domain-1 may confer a catalytic activity other than serine/threonine or tyrosine phosphorylation. For example, sub-domain VI_(a) is poorly conserved with respect to the equivalent motifs in the outer kinase families, and the normally invariant -ASP-PHE-GLY- sequence of the PTK and threonine/serine kinase families (sub-domain VII_(a)) is replaced by the motif ASP-PRO-GLY- in Domain-1 of JAK1. As has been noted elsewhere, the conservation of the precise sequence of sub-domain VI in the PTK and threonine/serin kinase families appears to correlate with the substrate specificity of the kinase. Thus, it is possible that Domain-1 of the JAK1 kinase has a substrate specificity other than that exhibited by the PTK and threonine/serine kinase has a substrate specificity other than that exhibited by the PTK and threonine/serine kinases. In support of this notion there are subtle differences in the normally consistent spacing between certain key motifs in Domain-1 of JAK1. The components of the ATP binding site (sub-domains I_(a) and II_(a)) are some 7 amino acids further apart in this domain that they are in both the PTK family and the threonine/serine kinase family. Moreover, the spacing between sub-domains VI_(a) and VII_(a) in this region is also longer by 9 amino acids. Conversely, the distance between sub-domains VII_(a) and IX_(a) is 7 amino acids shorter than the corresponding region in the PTK catalytic domain. The overall structure of this domain can be expected to be somewhat different to the catalytic domains of the members of the PTK and threonine/serine kinase families.

The sequences N-terminal to Domain-1 bear no homology to any other portion of a previously described protein kinase. Specifically, no homology was detected to the SH2 domain described for the cytoplasmic PTKs such as c-fex/fps. (Sadowski et al, 1986) GAP (Trahey et al, 1988) and the phospholipase-C family of proteins (Suh et al, 1988). This is a particularly interesting observation since no other non-receptor PTK has been described which lacks this feature. A hydrophilicity plot failed to demonstrate the present of a hydrophobic domain characteristic of the growth factor receptor type of PTK (FIG. 3b) suggesting that this protein is wholly intracellar like, other members of the non-receptor class of PTKs. The one outstanding feature of the JAK1 hydropathy plot is the highly hydrophilic sequence between residues 320-350. This sequence is not conserved in the murine JAK2 protein, however, its remarkable nature suggests that it may well be involved in some function of the JAK1 protein.

Expression of JAK1 protein

Several antisera were generated against the human JAK1 protein. Polyclonal antisera directed against the hexadecamer -TSFONLIECFEALLKC- (SEQ ID No: 4) (the C terminal 15 amino acids of JAK1) were raised in rabbits and used to investigate the nature of the JAK1 protein. A second rabbit antiserum was generated using a pGEX bacterial fusion protein containing the entire Domain-1 region of the human JAK1 protein (see Example 1). Preliminary sequence analysis of cDNA clones of murine JAK1 demonstrated that the C-terminus of the human and murine versions of this protein were identical whereas the murine and human Domain-1 regions exhibited a very high degree of identity. Both systems have thus been used interchangeably in the investigation of the properties of the JAK1 protein.

Both antisera have been used for Western blot analyses and immunoprecipitation studies and the data confirm the mRNA expression studies shown in FIG. 1. For example, antisera M3 and M8 both immunoprecipitate a protein of the same apparent molecular weight (130 kDaltons) from ³⁵ S-methionine labelled murine breast fibroblasts (FIG. 4a). From the same source, ³² P-orthophosphate labelled JAK1 was immunoprecipitated as a phosphothreonine and phosphoserine containing phosphorprotein. It is a feature characteristic of members of the protein tyrosine kinase family that they are able to accomplish an act of self phosphorylation in vitro. Intriguingly, despite the high degree of sequence similarity held by the PTK-related sequence of JAK1 to the PTK family in general, it was not possible to demonstrate tyrosine kinase catalytic activity in immunoprecipitates of this protein from any of the murine or human sources tested. A wide range of possibilities has been tested in search of suitable conditions for the demonstration of this activity. These are listed in Example 1. The reason for the lack of activity may lie with a steric effect of the antibody in the active site of the enzyme.

In order to determine whether domain 1 or the PTK domain, in isolation, bore catalytic activity, bacterial fusion proteins of each were generated with the glutathione transferase protein of Schistosoma japonicum (Smith and Johnson, 1988) and an attempt was made to demonstrate with the aid of anti-phosphotyrosine antibodies (Kamps and Sefton, 1988) the co-ordinate induction of the fusion protein and tyrosine phosphorylated protein. In this system there is no cross-reactive background of the anti-phosphotyrsine antiserum, since there are not tyrosine kinases in bacteria (FIG. 4b). The phosphorylation of bacterial proteins on tyrosine is thus easily detectable with such a serum. In this series of experiments neither pGEX without insert nor pGEX bearing Domain-1 (pGEX/JAK/1/1) demonstrated any tyrosine kinase activity. The pGEX/JAK/1 fusion protein was further purified by affinity chromatography on a reduced glutathione column and have failed to detect any kinase activity using either histones, casein or enolase as an exogenous substrate. The pattern of inducible tyrosine phosphorylation exhibited by the pGEX PTK fusion protein (pGEX/JAK/2) (FIG. 4b) is ususually simple for an ectopically expressed PTK fusion protein. Remarkably, the autophosphorylation of the fusion protein itself does not seem to occur, an observation which may go some way toward explaining why we have had difficulty in demonstrating PTK activity in the intact protein.

cDNA clones covering the coding region of the PCR clone FD17 (JAK2) have been isolated from a range of murine cDNA libraries. The predicted amino acid sequences of JAK2 and JAK1 show several regions of significant similarity to each other (FIG. 5, see also Example 3).

Phylogenetic analysis

The phylogenetic relationship of the catalytic domains of must of the protein kinases has been determined using the tree-building programme of Feng and Doolittle (1987). FIG. 6 shows the phylogenetic relationship of the two kinase-related domains of the JAK1 protein to the rest of the kinase family. It is concluded from this family tree that these two domains had a common ancestor which pre-dated the development of the PTK sub-family. It is of interest to note that the kinase related domains of the ANP-receptor/guanylate cyclase family diverge at a point close by.

EXAMPLE 3 Cloning and sequencing of JAK2

Sequence of Murine JAK2

The PCR close FD17 was used as a basis to begin the cloning of longer cDNA clones of murine JAK2, cDNAs were isolated from a range of cDNA libraries, and by RACE (Frohman et al, 1989, Loh et al, 1989). The sequence of murine JAK2 is presented in FIG. 8. The predicted amino acid sequence indicates that this protein is highly related to JAK1. At the C-terminus, and extending approximately 270 amino acids towards the N-terminus (AA 715-980), are sequences bearing all the hall marks of a PTK catalytic domain. These are labelled in FIG. 8 according to the Hanks nomenclature. Immediately N-terminal to this (AA 400-600) lies the kinase-related domain characteristic of this class of PTKs (Wilks et al, 1991). The approach outlined in Example 2 in relation to JAK1 was followed and assigned these kinase related domains according to the Hanks nomenclature, appending the suffix Na to denote their origin. One unusual feature of this domain is an apparent insertion of seven amino acids between elements VIIa and VIIIa (Hanks nomenclature; Hanks and Quinn, 1991) with respect to other members of this family. This feature appeared in only one clone of the four sequenced which covered this region, and it remains possible that its presence is due to an infrequent splicing abberation, rather than being of functional significance.

Distribution of JAK2

Northern analysis of the expression of JAK2 in the mouse demonstrated tow mRNA transcripts (4.8 and 4.4 kb) hybridizing to the JAK2 probe under low and high stringency hybridization conditions (FIG. 9). It is intriguing to note that the levels of these transcripts alter with respect to one another in different tissues. For example, the kidney, spleen and lung appear to express predominantly the larger form, whereas ovary, placenta, skeletal (sk) muscle and all murine cell lines analyzed express both forms at about equal levels. Under low stringency hybridization conditions the murine JAK2 probe recognizes human JAK2 RNA (K562), however, only the smaller transcript of 4.4 kb could be detected. At this point, the origins of either of the two transcripts are unclear and no differential splicing events which could account for the differences between them could be detected. However, the major source of size differential in these transcripts may lie in the use of different poly-adenylation signals. JAK2 is widely expressed in mouse organs, albeit to different levels. High expression was found in thymus, skeletal muscle, ovary and placenta, but JAK2 transcripts were barely detectable in testes or liver. In addition, JAK2 expression was detected in murine cell lines of fibroblastic (30F, NIH), epithelial (3ID) and hemopoietic (30.1) origin.

JAK Family Homology Domains

The cloning of JAK1 and JAK2 has facilitated the identification of JAK family homology domains. FIG. 10 shows a comparison of the amino acid sequences of JAK1. Sequence identity between these two proteins manifests itself as seven clearly defined homology domains. These seven domains are defined at a primary sequences level in FIG. 11. The PTK domain is classified as the JAK-homology Domain 1 (Hl), the second kinase related domain as the JH2 Domain, and so on to JH7. The boundaries of the JAK homology domains are arbitrary, and may or may not define functional domains. However, their delineation is a useful device to aid the consideration of the overall structural similarity of this class of proteins. The structure of the JH1 and JH2 Domains are described in Example 2. The JH3 is one of the least highly conserved of the JAK homology domains, each family member bearing between 35% (JAK2) to 50% (JAK1) of the deduced consensus sequence. The JH4 domain bears the sequence -GLYVLRWS- (SEQ. ID. No: 11) close to its C-terminal boundary, which has some degree of homology to the SH2 domain core sequence (see below). In addition, the most highly conserved sub-domain of this region bears a potential tyrosine phosphorylation site, namely, -VDGYFRI- (SEQ. ID. No: 12). Overall, the JH4 domain has between 51% (JAK2) and 64% (JAK1) of the deduced consensus sequence for this domain. Each of the remaining JAK, homology domains has been independently screened against the NKR1, and EMBL databases using the FASTA programme. There were no compelling homologies found with anything in these databases. It is concluded that these domains are structurally and functionally conserved in members of the JAK family of PTKs, but may not, in contradistinction to the SH2 and SH3 domains of the arc family of PTKs, have a role to play in other signal transduction molecules.

The apparent absence of an SH2 domain in any of the JAK family of PTKs is intriguing. Subtle sequence similarities have been detected between SH2 consensus sequences and portions of the JH3 and JH4 domains (H. Hanafusa and A. Bernards, personal communication). FIG. 12 shows an alignment of these two domains. Whilst the similarity of the JH3 domain to SH2 domains is most evident in the region surrounding the SH2 core sequence (FLVRES), the homology does not extend far in either direction beyond this region, and only reappears again close to the C-terminal boundary of the SH2 domain. This lack of extensive homology, particularly in many of those elements most highly conserved between SH2 domains (Koch et al., 1991) (presumably indicating those residues most intimately involved in the conserved function of this domain), suggests that the homology detected is either happenstance, or the product of considerable sequence divergence in evolution. The SH2 domain is currently believed to interact with phosphorylated tyrosine residues on the substrates of PTKs (reviewed in Pawson, 1989; Koch et al, 1991). Whether the JH3/JH4 domains play a similar functional role remaining to be determined.

EXAMPLE 4

To show that JAKs are represented in a range of animals, oligonucleotide probes were prepared and used to amplify and screen genomes from a variety of animals. JAK DNA was detected in Drosophila, Xenopus, mouse and human genomes. The main conserved sequence was DPG common to all animals tested.

REFERENCES

Claesson-Welsh, L., Eriksson, A., Westermark, B. and Heldin, C. H., Proc Nat. Acad. Sci., USA 86: 4917-4921, 1989.

Feng, D. F. and Doolittle, R. F. Jour. Mol. Evolution 25: 351-360, 1987.

Fitch, W. M. and Margoliash, E., Science 12: 279-284, 1967.

Hunter, T., and Sefton, B. M. Proc. Nat. Acad. Sci. 77: 1311-1315, 1980.

Kamps, M. P., and Sefton, B. M. Oncogene 2: 305-315, 1988.

Kozak, M. Nucleic Acids Res. 12: 857-872, 1984.

Kozma, S. C. Redmond, S. M. S., Xiano-Chan, F., Saurer, S. M. Groner, B., and Hynes, N. E. EMBO J. 7: 147-154, 1988.

Kyte, J. and Doolittle, R. F. J. Mol. Biol, 157: 105-132, 1982.

Laemmli, U. K. Nature (London) 227: 680-685, 1970.

Lee, M. G. and Nurse, P. Nature (London) 327: 31÷35, 1987.

Maniatis, T., Fritsch, E. T., and Sambrook, J., in Molecular Cloning: A Laboratory Manual Cold Spring Harbor, N.Y. 1982.

Moran, M. F., Koch, C. A., Sadowksi, I., and Pawson, T. Oncogene 3: 665-672, 1988.

Reichmann, E., Ball, R., Groner, B., and Friis, R. R. J. Cell Bio, 108: 1127-1138, 1989.

Smith, D. B. and Johnson, K. S. Gene 67: 31-40, 1988.

Suh, P., Ryu, S. H., Moon, K. H., Suh, H. W., and Rhee, S. G. Cell 54: 161-169, 1988.

Towbin, H., Stehelin, T., and Gordon, J., Proc. Nat. Acad. Sci. USA 76: 4350-4354, 1970.

Weinmaster, G., Zoller, M. M., Smith, M., Hinze, H., and Pawson, T. Cell 37: 559-568, 1984.

Wilks, A. F. and Kurban, R. H. Oncogene 3: 289-294, 1988.

Ziemiecki, A., Mueller, R. G., Xiao-Chan, F., Hynes, N. E. and Koznia, S., EMBO J., 9: 191-196, 1990.

Dymecki, S. M., Neiderhuber, J. E., and Desiderio, S.v. Science 247: 332-336, 1990.

Firmback-Kraft, I., Byers, M., Showes, T., Dalla-Favera, R., and Krolewski, J. J., Oncogene 5: 1329-1336, 1990.

Frohman, M. A., Dush, J. M. and Martin, G., Proc. Nat. Acad. Sci. USA 85: 8998-9002, 1988.

Hanks, S. K. and Quinn, A. M. Methods in Enzymology 200: 38-62, 1991.

Hanks, S. K., Quinn, A. M. and Hunter, T. Science 241: 42-52, 1988.

Higgins, D. G. and Sharp, P. M. Gene 73: 237-244, 1988.

Holtzman, D. A., Cook, W. D. and Dunn, A. R. Proc. Natl. Acad. Sci. USA 84: 8325-8329, 1987.

Koch, C. A., Anderson, D., Moran, M. F., Ellis, C., and Pawson, T., 252: 668-674, 1991.

Loh, E. Y., Elliott, J. F., Cwirla, S., Lanier, T. D. and Davis, M. M. Science 243: 217-220, 1989.

Marth, J. D., Peet, R., Krebs, E. G., and Perimutter, R. M. Cell 43: 393-404, 1985.

Martinez, R., Mathey-Prevot, B., Bernards, A. and Baltimore, D. Science 237: 411-414, 1987.

Mayer, B. I., Hamaguchi, H., and Hanafusa, H., Nature 332: 272-274, 1988.

Nishizawa, M., Semba, K., Yoshida, M. C. Yamamoto, T., Sasaki, M., and Toyoshima, K. Mol. Cell Biol. 6: 511-517, 1986.

Pawson, T., Oncogene 3: 491-495, 1988.

Pearson, W. R. and Lippman, D. J. Proc. Natl. Acad. Sci. 85: 2444-2448, 1988.

Reid, H. H., Wilks, A. F., and Bernard, O., Proc. Nat. Acad. Sci. 87:14 1596-1600, 1990.

Sadowski, L., Stone, J. C., and Pawson, T. Mol. Cell. Biol. 6: 4396-4408, 1986.

Sanger, F., Nickleu, S., and Couson, A. R., Proc. Nat. Acad. Sci. USA 74: 5463-5467, 1977.

Semba, K., Nishizawa, M., Myajima, N., Yoshida, M. C., Sukagawa, J., Yamanishi, Y., Sasaki, M., Yamamoto, T., and Toyoshima, K., Proc. Natl. Acad. Sci. 83: 5459-5463, 1986.

Sukagawa, J., Semba, K., Yamanashi, Y., Nishizawa, M., Myajima, N., Kamamoto, T., and Toyoshima, K., Mol. Cell. Biol. 7: 41-47, 1987.

Trahey, M., Wong, G., Halenbeck, R., Rubinfeld, B., Martin, G. A., Ladner, M., Long, C. M., Crosier, W. J., Watt, K., Koths, K., and McCormick, F., Science 243: 1697-1700, 1988.

Wilks., A. F., Process in Growth Factor Research 2: 97-111, 1990.

Wilks, A. F., Harpur, A., Kurban, R. R., Ralph, S. J., Zuercher, G., and Ziemiecki, A. Molecular and Cellular Biology 11: 2057-2065, 1991.

Yamasmishi, Y., Pukishige, S. I., Semba, K., Sukegawa, J., Miyayjima, N., Matsubara, K. I., Yamamoto, T., and toyoshima, K., Molec. Cell. Biol. 7: 237-243, 1987.

    __________________________________________________________________________     SEQUENCE LISTING                                                               (1) GENERAL INFORMATION:                                                       (iii) NUMBER OF SEQUENCES: 23                                                  (2) INFORMATION FOR SEQ ID NO:1:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 4234 base pairs                                                    (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (ii) MOLECULE TYPE: nucleic acid                                               (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:                                       TGGCCGCCTAGCGAGCTGCCGGTCGACCCCAGCCAGCCGAGCGACGGGCGCTGCCTGGCC60                 CAGGGCACACGGAAGTGCGCTTCTCTGAAGTAGCTTTGGAAAGTAGAGAAGAAAATCCAG120                TTTGCTTCTTGGAGAACACTGGACAGCTGAATAAATGCAGTATCTAAAT169                           MetGlnTyrLeuAsn                                                                10                                                                             ATAAAAGAGGACTGCAATGCCATGGCTTTCTGTGCTAAAATGAGG214                               IleLysGluAspCysAsnAlaMetAlaPheCysAlaLysMetArg                                  5+15                                                                           AGCTCCAAGAAGACTGAGGTGAACCTGGAGGCCCCTGAGCCAGGG259                               SerSerLysLysThrGluValAsnLeuGluAlaProGluProGly                                  101520                                                                         GTGGAAGTGATCTTCTATCTGTCGGACAGGGAGCCCCTCCGGCTG304                               ValGluValIlePheTyrLeuSerAspArgGluProLeuArgLeu                                  253035                                                                         GGCAGTGGAGAGTACACAGCAGAGGAACTGTGCATCAGGGCTGCA349                               GlySerGlyGluTyrThrAlaGluGluLeuCysIleArgAlaAla                                  404550                                                                         CAGGCATGCCGTATCTCTCCTCTTTGTCACAACCTCTTTGCCCTG394                               GlnAlaCysArgIleSerProLeuCysHisAsnLeuPheAlaLeu                                  556065                                                                         TATGACGAGAACACCAAGCTCTGGTATGCTCCAAATCGCACCATC439                               TyrAspGluAsnThrLysLeuTrpTyrAlaProAsnArgThrIle                                  707580                                                                         ACCGTTGATGACAAGATGTCCCTCCGGCTCCACTACCGGATGAGG484                               ThrValAspAspLysMetSerLeuArgLeuHisTyrArgMetArg                                  859095                                                                         TTCTATTTCACCAATTGGCATGGAACCAACGACAATGAGCAGTCA529                               PheTyrPheThrAsnTrpHisGlyThrAsnAspAsnGluGlnSer                                  100105110                                                                      GTGTGGCGTCATTCTCCAAAGAAGCAGAAAAATGGCTACGAGAAA574                               ValTrpArgHisSerProLysLysGlnLysAsnGlyTyrGluLys                                  115120125                                                                      AAAAAGATTCCAGATGCAACCCCTCTCCTTGATGCCAGCTCACTG619                               LysLysIleProAspAlaThrProLeuLeuAspAlaSerSerLeu                                  130135140                                                                      GAGTATCTGTTTGCTCAGGGACAGTATGATTTGGTGAAATGCCTG664                               GluTyrLeuPheAlaGlnGlyGlnTyrAspLeuValLysCysLeu                                  145150155                                                                      GCTCCTATTCGAGACCCCAAGACCGAGCAGGATGGACATGATATT709                               AlaProIleArgAspProLysThrGluGlnAspGlyHisAspIle                                  160165170                                                                      GAGAACGAGTGTCTAGGGATGGCTGTCCTGGCCATCTCACACTAT754                               GluAsnGluCysLeuGlyMetAlaValLeuAlaIleSerHisTyr                                  175180185                                                                      GCCATGATGAAGAAGATGCAGTTGCCAGAACTGCCCAAGGACATC799                               AlaMetMetLysLysMetGlnLeuProGluLeuProLysAspIle                                  190195200                                                                      AGCTACAAGCGATATATTCCAGAAACATTGAATAAGTCCATCAGA844                               SerTyrLysArgTyrIleProGluThrLeuAsnLysSerIleArg                                  205210215                                                                      CAGAGGAACCTTCTCACCAGGATGCGGATAAATAATGTTTTCAAG889                               GlnArgAsnLeuLeuThrArgMetArgIleAsnAsnValPheLys                                  220225230                                                                      GATTTCCTAAAGGAATTTAACAACAAGACCATTTGTGACAGCAGC934                               AspPheLeuLysGluPheAsnAsnLysThrIleCysAspSerSer                                  235240245                                                                      GTGTCCACGCATGACCTGAAGGTGAAATACTTGGCTACCTTGGAA979                               ValSerThrHisAspLeuLysValLysTyrLeuAlaThrLeuGlu                                  250255260                                                                      ACTTTGACAAAACATTACGGTGCTGAAATATTTGAGACTTCCATG1024                              ThrLeuThrLysHisTyrGlyAlaGluIlePheGluThrSerMet                                  265270275                                                                      TTACTGATTTCATCAGAAAATGAGATGAATTGGTTTCATTCGAAT1069                              LeuLeuIleSerSerGluAsnGluMetAsnTrpPheHisSerAsn                                  280285290                                                                      GACGGTGGAAACGTTCTCTACTACGAAGTGATGGTGACTGGGAAT1114                              AspGlyGlyAsnValLeuTyrTyrGluValMetValThrGlyAsn                                  295300305                                                                      CTTGGAATCCAGTGGAGGCATAAACCAAATGTTGTTTCTGTTGAA1159                              LeuGlyIleGlnTrpArgHisLysProAsnValValSerValGlu                                  310315320                                                                      AAGGAAAAAAATAAACTGAAGCGGAAAAAACTGGAAAATAAAGAC1204                              LysGluLysAsnLysLeuLysArgLysLysLeuGluAsnLysAsp                                  325330335                                                                      AAGAAGGATGAGGAGAAAAACAAGATCCGGGAAGAGTGGAACAAT1249                              LysLysAspGluGluLysAsnLysIleArgGluGluTrpAsnAsn                                  340345350                                                                      TTTTCATTCTTCCCTGAAATCACTCACATTGTAATAAAGGAGTCT1294                              PheSerPhePheProGluIleThrHisIleValIleLysGluSer                                  355360365                                                                      GTGGTCAGCATTAACAAGCAGGACAACAAGAAAATGGAACTGAAG1339                              ValValSerIleAsnLysGlnAspAsnLysLysMetGluLeuLys                                  370375380                                                                      CTCTCTTCCCACGAGGAGGCCTTGTCCTTTGTGTCCCTGGTAGAT1384                              LeuSerSerHisGluGluAlaLeuSerPheValSerLeuValAsp                                  385390395                                                                      GGCTACTTCCGGCTCACAGCAGATGCCCATCATTACCTCTGCACC1429                              GlyTyrPheArgLeuThrAlaAspAlaHisHisTyrLeuCysThr                                  400405410                                                                      GACGTGGCCCCCCCGTTGATCGTCCACAACATACAGAATGGCTGT1474                              AspValAlaProProLeuIleValHisAsnIleGlnAsnGlyCys                                  415420425                                                                      CATGGTCCAATCTGTACAGAATACGCCATCAATAAATTGCGGCAA1519                              HisGlyProIleCysThrGluTyrAlaIleAsnLysLeuArgGln                                  430435440                                                                      GAAGGAAGCGAGGAGGGGATGTACGTGCTGAGGTGGAGCTGCACC1564                              GluGlySerGluGluGlyMetTyrValLeuArgTrpSerCysThr                                  445450455                                                                      GACTTTGACAACATCCTCATGACCGTCACCTGCTTTGAGAAGTCT1609                              AspPheAspAsnIleLeuMetThrValThrCysPheGluLysSer                                  460465470                                                                      GAGCAGGTGCAGGGTGCCCAGAAGCAGTTCAAGAACTTTCAGATC1654                              GluGlnValGlnGlyAlaGlnLysGlnPheLysAsnPheGlnIle                                  475480485                                                                      GAGGTGCAGAAGGGCCGCTACAGTCTGCACGGTTCGGACCGCAGC1699                              GluValGlnLysGlyArgTyrSerLeuHisGlySerAspArgSer                                  490495500                                                                      TTCCCCAGCTTGGGAGACCTCATGAGCCACCTCAAGAAGCAGATC1744                              PheProSerLeuGlyAspLeuMetSerHisLeuLysLysGlnIle                                  505510515                                                                      CTGCGCACGGATAACATCAGCTTCATGCTAAAACGCTGCTGCCAG1789                              LeuArgThrAspAsnIleSerPheMetLeuLysArgCysCysGln                                  520525530                                                                      CCCAAGCCCCGAGAAATCTCCAACCTGCTGGTGGCTACTAAGAAA1834                              ProLysProArgGluIleSerAsnLeuLeuValAlaThrLysLys                                  535540545                                                                      GCCCAGGAGTGGCAGCCCGTCTACCCCATGAGCCAGCTGAGTTTC1879                              AlaGlnGluTrpGlnProValTyrProMetSerGlnLeuSerPhe                                  550555560                                                                      GATCGGATCCTCAAGAAGGATCTGGTGCAGGGCGAGCACCTTGGG1924                              AspArgIleLeuLysLysAspLeuValGlnGlyGluHisLeuGly                                  565570575                                                                      AGAGGCACGAGAACACACATCTATTCTGGGACCCTGATGGATTAC1969                              ArgGlyThrArgThrHisIleTyrSerGlyThrLeuMetAspTyr                                  580585590                                                                      AAGGATGACGAAGGAACTTCTGAAGAGAAGAAGATAAAAGTGATC2014                              LysAspAspGluGlyThrSerGluGluLysLysIleLysValIle                                  595600605                                                                      CTCAAAGTCTTAGACCCCAGCCACAGGGATATTTCCCTGGCCTTC2059                              LeuLysValLeuAspProSerHisArgAspIleSerLeuAlaPhe                                  605615620                                                                      TTCGAGGCAGCCAGCATGATGAGACAGGTCTCCCACAAACACATC2104                              PheGluAlaAlaSerMetMetArgGlnValSerHisLysHisIle                                  625630635                                                                      GTGTACCTCTATGGCGTCTGTGTCCGCGACGTGGAGAATATCATG2149                              ValTyrLeuTyrGlyValCysValArgAspValGluAsnIleMet                                  640645650                                                                      GTGGAAGAGTTTGTGGAAGGGGGTCCTCTGGATCTCTTCATGCAC2194                              ValGluGluPheValGluGlyGlyProLeuAspLeuPheMetHis                                  655660665                                                                      CGGAAAAGTGATGTCCTTACCACACCATGGAAATTCAAAGTTGCC2239                              ArgLysSerAspValLeuThrThrProTrpLysPheLysValAla                                  670675680                                                                      AAACAGCTGGCCAGTGCCCTGAGCTACTTGGAGGATAAAGACCTG2284                              LysGlnLeuAlaSerAlaLeuSerTyrLeuGluAspLysAspLeu                                  685690695                                                                      GTCCATGGAAATGTGTGTACTAAAAACCTCCTCCTGGCCCGTGAG2329                              ValHisGlyAsnValCysThrLysAsnLeuLeuLeuAlaArgGlu                                  700705710                                                                      GGAATCGACAGTGAGTGTGGCCCATTCATCAAGCTCAGTGACCCC2374                              GlyIleAspSerGluCysGlyProPheIleLysLeuSerAspPro                                  715720725                                                                      GGCATCCCCATTACGGTGCTGTCTAGGCAAGAATGCATTGAACGA2419                              GlyIleProIleThrValLeuSerArgGlnGluCysIleGluArg                                  730735740                                                                      ATCCCATGGATTGCTCCTGAGTGTGTTGAGGACTCCAAGAACCTG2464                              IleProTrpIleAlaProGluCysValGluAspSerLysAsnLeu                                  745750755                                                                      AGTGTGGCTGCTGACAAGTGGAGCTTTGGAACCACGCTCTGGGAA2509                              SerValAlaAlaAspLysTrpSerPheGlyThrThrLeuTrpGlu                                  760765770                                                                      ATCTGCTACAATGGCGAGATCCCCTTGAAAGACAAGACGCTGATT2554                              IleCysTyrAsnGlyGluIleProLeuLysAspLysThrLeuIle                                  775780785                                                                      GAGAAAGAGAGATTCTATGAAAGCCGGTGCAGGCCAGTGACACCA2599                              GluLysGluArgPheTyrGluSerArgCysArgProValThrPro                                  790795800                                                                      TCATGTAAGGAGCTGGCTGACCTCATGACCCGCTGCATGAACTAT2644                              SerCysLysGluLeuAlaAspLeuMetThrArgCysMetAsnTyr                                  805810815                                                                      GACCCCAATCAGAGGCCTTTCTTCCGAGCCATCATGAGAGACATT2689                              AspProAsnGlnArgProPhePheArgAlaIleMetArgAspIle                                  820825830                                                                      AATAAGCTTGAAGAGCAGAATCCAGATATTGTTTCCAGAAAAAAA2734                              AsnLysLeuGluGluGlnAsnProAspIleValSerArgLysLys                                  835840845                                                                      AACCAGCCAACTGAAGTGGACCCCACACATTTTGAGAAGCGCTTC2779                              AsnGlnProThrGluValAspProThrHisPheGluLysArgPhe                                  850855860                                                                      CTAAAGAGGATCCGTGACTTGGGAGAGGGCCACTTTGGGAAGGTT2824                              LeuLysArgIleArgAspLeuGlyGluGlyHisPheGlyLysVal                                  865870875                                                                      GAGCTCTGCAGGTATGACCCCGAAGACAATACAGGGGAGCAGGTG2869                              GluLeuCysArgTyrAspProGluAspAsnThrGlyGluGlnVal                                  880885890                                                                      GCTGTTAAATCTCTGAAGCCTGAGAGTGGAGGTAACCACATAGCT2914                              AlaValLysSerLeuLysProGluSerGlyGlyAsnHisIleAla                                  895900905                                                                      GATCTGAAAAAGGAAATCGAGATCTTAAGGAACCTCTATCATGAG2959                              AspLeuLysLysGluIleGluIleLeuArgAsnLeuTyrHisGlu                                  910915920                                                                      AACATTGTGAAGTACAAAGGAATCTGCACAGAAGACGGAGGAAAT3004                              AsnIleValLysTyrLysGlyIleCysThrGluAspGlyGlyAsn                                  925930935                                                                      GGTATTAAGCTCATCATGGAATTTCTGCCTTCGGGAAGCCTTAAG3049                              GlyIleLysLeuIleMetGluPheLeuProSerGlySerLeuLys                                  940945950                                                                      GAATATCTTCCAAAGAATAAGAACAAAATAAACCTCAAACAGCAG3094                              GluTyrLeuProLysAsnLysAsnLysIleAsnLeuLysGlnGln                                  955960965                                                                      CTAAAATATGCCGTTCAGATTTGTAAGGGGATGGACTATTTGGGT3139                              LeuLysTyrAlaValGlnIleCysLysGlyMetAspTyrLeuGly                                  970975980                                                                      TCTCGGCAATACGTTCACCGGGACTTGGCAGCAAGAAATGTCCTT3184                              SerArgGlnTyrValHisArgAspLeuAlaAlaArgAsnValLeu                                  985990995                                                                      GTTGAGAGTGAACACCAAGTGAAAATTGGAGACTTCGGTTTAACC3229                              ValGluSerGluHisGlnValLysIleGlyAspPheGlyLeuThr                                  100010051010                                                                   AAAGCAATTGAAACCGATAAGGAGTATTACACCGTCAAGGATGAC3274                              LysAlaIleGluThrAspLysGluTyrTyrThrValLysAspAsp                                  101510201025                                                                   CGGGACAGCCCTGTGTTTTGGTATGCTCCAGAATGTTTAATGCAA3319                              ArgAspSerProValPheTrpTyrAlaProGluCysLeuMetGln                                  103010351040                                                                   TCTAAATTTTATATTGCCTCTGACGTCTGGTCTTTTGGAGTCACT3364                              SerLysPheTyrIleAlaSerAspValTrpSerPheGlyValThr                                  104510501055                                                                   CTGCATGAGCTGCTGACTTACTGTGATTCAGATTCTAGTCCCATG3409                              LeuHisGluLeuLeuThrTyrCysAspSerAspSerSerProMet                                  106010651070                                                                   GCTTTGTTCCTGAAAATGATAGGCCCAACCCATGGCCAGATGACA3454                              AlaLeuPheLeuLysMetIleGlyProThrHisGlyGlnMetThr                                  107510801085                                                                   GTCACAAGACTTGTGAATACGTTAAAAGAAGGAAAACGCCTGCCG3499                              ValThrArgLeuValAsnThrLeuLysGluGlyLysArgLeuPro                                  109010951100                                                                   TGCCCACCTAACTGTCCAGATGAGGTTTATCAGCTTATGAGAAAA3544                              CysProProAsnCysProAspGluValTyrGlnLeuMetArgLys                                  110511101115                                                                   TGCTGGGAATTCCAACCATCCAATCGGACAAGCTTTCAGAACCTT3589                              CysTrpGluPheGlnProSerAsnArgThrSerPheGlnAsnLeu                                  112011351130                                                                   ATTGAAGGATTTGAAGCACTTTTAAAATAAGAAGCATGAATAACATT3636                            IleGluGlyPheGluAlaLeuLeuLys                                                    11351140                                                                       TAAATTCCACAGATTATCAAGTCCTTCTCCTGCAACAAATGCCCAAGTCATTTTTTAAAA3696               ATTTCTAATGAAAGAAGTTTGTGTTCTGTCCAAAAAGTCACTGAACTCATACTTCAGTAC3756               ATATACATGTATAAGGCACACTGTAGTGCTTAATATGTGTAAGGACTTCCTCTTTAAATT3816               TGCACCAGTAACTTAGTGACACATAATGACAACCAAAATATTTGAAAGCACTTAAGCACT3876               CCTCCTTGTGGAAAGAATATACCACCATTTCATCTGGCTAGTTCACCATCACAACTGCAT3936               TACCAAAAGGGGATTTTTGAAAACGAGGAGTTGACCAAAATAATATCTGAAGATGATTGC3996               TTTTCCCTGCTGCCAGCTGACTGAAATGTTTTCCTGGCACATTAATCATAGATAAAGAAG4056               ATTGATGGACTTAGCCCTCAAACAGTATCTATACAGTACTAGACCATGCATTCTTAAAAT4116               ATTAGATACCAGGTAGTATATATTGTTTCTGTACAAAAATGACTGTATTCTCTCACCAGT4176               AGGACTTAAACTTTGTTTCTCCAGTGGCTTAGCTCCTGTTCCTTTGGGTGATCACTAG4234                 (2) INFORMATION FOR SEQ ID NO:2:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 3495 base pairs                                                    (B) TYPE: nucleic acid                                                         (D) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (ii) MOLECULE TYPE: nucleic acid                                               (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:                                       CTGCTTGATGACTTTGTCATGTCTTACCTTTCCCCTCAGTGGCGG45                                LeuLeuAspAspPheValMetSerTyrLeuSerProGlnTrpArg                                  151015                                                                         CATGATTTTGTTCACGGATGGATAAAAGTACCTGTGACTCATGAA90                                HisAspPheValHisGlyTrpIleLysValProValThrHisGlu                                  202530                                                                         ACTCAGGAAGAGTGTCTTGGGATGGCGGTGTTAGACATGATGAGA135                               ThrGlnGluGluCysLeuGlyMetAlaValLeuAspMetMetArg                                  354045                                                                         ATAGCTAAGGAGAAAGACCAGACTCCACTGGCTGTCTATAACTCT180                               IleAlaLysGluLysAspGlnThrProLeuAlaValTyrAsnSer                                  505560                                                                         GTCAGCTACAAGACATTCTTACCAAAGTGCGTTCGAGCGAAGATC225                               ValSerTyrLysThrPheLeuProLysCysValArgAlaLysIle                                  657075                                                                         CAAGACTATCACATTTTAACCCGGAAGCGAATCAGGTACAGATTT270                               GlnAspTyrHisIleLeuThrArgLysArgIleArgTyrArgPhe                                  808590                                                                         CGCAGATTCATTCAGCAATTCAGTCAATGTAAAGCCACTGCCAGG315                               ArgArgPheIleGlnGlnPheSerGlnCysLysAlaThrAlaArg                                  95100105                                                                       AACCTAAAACTTAAGTATCTTATAAACCTGGAAACCCTGCAGTCT360                               AsnLeuLysLeuLysTyrLeuIleAsnLeuGluThrLeuGlnSer                                  110115120                                                                      GCCTTCTACACAGAACAGTTTGAAGTAAAAGAATCTGCAAGAGGT405                               AlaPheTyrThrGluGlnPheGluValLysGluSerAlaArgGly                                  125130135                                                                      CCTTCAGGTGAGGAGATTTTTGCAACCATTATAATAACTGGAAAC450                               ProSerGlyGluGluIlePheAlaThrIleIleIleThrGlyAsn                                  140145150                                                                      GGTGGAATTCAGTGGTCAAGAGGGAAACATAAGGAAAGTGAGACA495                               GlyGlyIleGlnTrpSerArgGlyLysHisLysGluSerGluThr                                  155160165                                                                      CTGACAGAACAGGACGTACAGTTATATTGTGATTTCCCTGATATT540                               LeuThrGluGlnAspValGlnLeuTyrCysAspPheProAspIle                                  170175180                                                                      ATTGATGTCAGTATTAAGCAAGCAAATCAGGAATGCTCAACTGAA585                               IleAspValSerIleLysGlnAlaAsnGlnGluCysSerThrGlu                                  185190195                                                                      AGTAGAGTTGTGACCGTCCACAAGCAGGACGGGAAGGTCTTGGAA630                               SerArgValValThrValHisLysGlnAspGlyLysValLeuGlu                                  200205210                                                                      ATAGAACTTAGCTCATTAAAAGAAGCCTTGTCATTCGTGTCATTA675                               IleGluLeuSerSerLeuLysGluAlaLeuSerPheValSerLeu                                  215220225                                                                      ATTGACGGGTATTACAGACTAACTGCGGATGCACACCATTACCTC720                               IleAspGlyTyrTyrArgLeuThrAlaAspAlaHisHisTyrLeu                                  230235240                                                                      TGCAAAGAGGTGGCTCCCCCAGCTGTGTTCGAGAACATACACAGC765                               CysLysGluValAlaProProAlaValPheGluAsnIleHisSer                                  245250255                                                                      AACTGCCACGGCCCAATTTCAATGGATTTTGCCATCAGCAAACTA810                               AsnCysHisGlyProIleSerMetAspPheAlaIleSerLysLeu                                  260265270                                                                      AAGAAGGCAGGAAACCAGACTGGACTGTATGTACTTCGATGTAGC855                               LysLysAlaGlyAsnGlnThrGlyLeuTyrValLeuArgCysSer                                  275280285                                                                      CCTAAGGACTTCAACAAATACTTCCTGACCTTTGCCGTTGAGCGA900                               ProLysAspPheAsnLysTyrPheLeuThrPheAlaValGluArg                                  290295300                                                                      GAAAATGTTATTGAATATAAACACTGTTTGATTACAAAGAATGAG945                               GluAsnValIleGluTyrLysHisCysLeuIleThrLysAsnGlu                                  305310315                                                                      AATGGAGAGTACAACCTCAGTGGGACTAAGAGGAACTTCAGTAGT990                               AsnGlyGluTyrAsnLeuSerGlyThrLysArgAsnPheSerSer                                  320325330                                                                      CTTAAGGACCTTTTGAATTGCTACCAGATGGAAACTGTGCGCTCA1035                              LeuLysAspLeuLeuAsnCysTyrGlnMetGluThrValArgSer                                  335340345                                                                      GACAGTATCATCTTCCAGTTCACCAAATGCTGTCCTCCAAAGCCG1080                              AspSerIleIlePheGlnPheThrLysCysCysProProLysPro                                  350355360                                                                      AAAGATAAATCAAACCTTCTTGTCTTCAGAACAAATGGTGTTTCT1125                              LysAspLysSerAsnLeuLeuValPheArgThrAsnGlyValSer                                  365370375                                                                      GATGTTCAGCTCTCACCAACATTACAGAGGCATAATAATGTGAAT1170                              AspValGlnLeuSerProThrLeuGlnArgHisAsnAsnValAsn                                  380385390                                                                      CAAATGGTGTTTCACAAAATCAGGAATGAAGATTTGATATTTAAT1215                              GlnMetValPheHisLysIleArgAsnGluAspLeuIlePheAsn                                  395400405                                                                      GAAAGCCTTGGCCAAGGCACTTTTACAAAAATATTTAAAGGTGTA1260                              GluSerLeuGlyGlnGlyThrPheThrLysIlePheLysGlyVal                                  410415420                                                                      AGAAGAGAAGTTGGAGATTATGGTCAGCTGCACGAAACCGAAGTT1305                              ArgArgGluValGlyAspTyrGlyGlnLeuHisGluThrGluVal                                  425430435                                                                      CTTTTGAAAGTCCTAGATAAAGCACATAGAAACTATTCAGAGTCT1350                              LeuLeuLysValLeuAspLysAlaHisArgAsnTyrSerGluSer                                  440445450                                                                      TTCTTTGAAGCAGCAAGCATGATGAGTCAGCTTTCTCACAAGCAT1395                              PhePheGluAlaAlaSerMetMetSerGlnLeuSerHisLysHis                                  455460465                                                                      TTGGTTTTGAATTATGGAGTATGTGTCTGTGGAGAGGAGAACATT1440                              LeuValLeuAsnTyrGlyValCysValCysGlyGluGluAsnIle                                  470475480                                                                      TTGGTTCAAGAGTTTGTAAAATTTGGATCACTGGATACATACCTG1485                              LeuValGlnGluPheValLysPheGlySerLeuAspThrTyrLeu                                  485490495                                                                      AAGAAGAACAAAAATTCTATAAATATATTATGGAAACTTGGAGTG1530                              LysLysAsnLysAsnSerIleAsnIleLeuTrpLysLeuGlyVal                                  500505510                                                                      GCGAAGCAGTTGGCATGGGCCATGCACTTCCTCGAAGAAAAATCC1575                              AlaLysGlnLeuAlaTrpAlaMetHisPheLeuGluGluLysSer                                  515520525                                                                      CTTATTCATGGGAATGTGTGTGCTAAAAATATCCTGCTTATCAGA1620                              LeuIleHisGlyAsnValCysAlaLysAsnIleLeuLeuIleArg                                  530535540                                                                      GAAGAAGACAGGAGAACGGGGAACCCACCTTTCATCAAACTTAGT1665                              GluGluAspArgArgThrGlyAsnProProPheIleLysLeuSer                                  545550555                                                                      GATCCTGGCATTAGCATTACAGTTCTACCGAAGGACATTTCTTCC1710                              AspProGlyIleSerIleThrValLeuProLysAspIleSerSer                                  560565570                                                                      TGTTGTTTCCAAGTTCTTCAGGAGAGAATACCATGGGTACCACCT1755                              CysCysPheGlnValLeuGlnGluArgIleProTrpValProPro                                  575580585                                                                      GAGTGCATTGAGAATCCTAAAAATCTAACTCTGGCAACAGACAAG1800                              GluCysIleGluAsnProLysAsnLeuThrLeuAlaThrAspLys                                  590595600                                                                      TGGAGCTTCGGGACCACTCTGTGGGAGATCTGCAGTGGAGGAGAT1845                              TrpSerPheGlyThrThrLeuTrpGluIleCysSerGlyGlyAsp                                  605610615                                                                      AAGCCCCTGAGTGCTCTGGATTCTCAAAGAAAGCTGCAGTTCTAT1890                              LysProLeuSerAlaLeuAspSerGlnArgLysLeuGlnPheTyr                                  620625630                                                                      GAAGATAAGCATCAGCTTCCTGCACCCAAGTGGACAGAGTTGGCA1935                              GluAspLysHisGlnLeuProAlaProLysTrpThrGluLeuAla                                  635640645                                                                      AACCTTATAAATAATTGCATGGACTATGAGCCAGATTTCAGGCCT1980                              AsnLeuIleAsnAsnCysMetAspTyrGluProAspPheArgPro                                  650655660                                                                      GCTTTCAGAGCTGTCATCCGTGATCTTAACAGCCTGTTTACTCCA2025                              AlaPheArgAlaValIleArgAspLeuAsnSerLeuPheThrPro                                  665670675                                                                      GATTATGAACTACTAACAGAAAATGACATGCTACCAAACATGAGA2070                              AspTyrGluLeuLeuThrGluAsnAspMetLeuProAsnMetArg                                  680685690                                                                      ATAGGTGCCCTAGGGTTTTCTGGTGCTTTTGAAGACAGGGACCCT2115                              IleGlyAlaLeuGlyPheSerGlyAlaPheGluAspArgAspPro                                  695700705                                                                      ACACAGTTTGAAGAGAGACACTTGAAGTTTCTACAGCAGCTTGGC2160                              ThrGlnPheGluGluArgHisLeuLysPheLeuGlnGlnLeuGly                                  710715720                                                                      AAAGGTAACTTCGGGAGTGTGGAGATGTGCCGCTATGACCCGCTG2205                              LysGlyAsnPheGlySerValGluMetCysArgTyrAspProLeu                                  725730735                                                                      CAGGACAACACTGGCGAGGTGGTCGCTGTGAAGAAACTCCAGCAC2250                              GlnAspAsnThrGlyGluValValAlaValLysLysLeuGlnHis                                  740745750                                                                      AGCACTGAAGAGCACCTCCGAGACTTTGAGAGGGAGATCGAGATC2295                              SerThrGluGluHisLeuArgAspPheGluArgGluIleGluIle                                  755760765                                                                      CTGAAATCCTTGCAGCATGACAACATCGTCAAGTACAAGGGAGTG2340                              LeuLysSerLeuGlnHisAspAsnIleValLysTyrLysGlyVal                                  770775780                                                                      TGCTACAGTGCGGGTCGGCGCAACCTAAGATTAATTATGGAATAT2385                              CysTyrSerAlaGlyArgArgAsnLeuArgLeuIleMetGluTyr                                  785790795                                                                      TTACCATATGGAAGTTTACGAGACTATCTCCAAAAACATAAAGAA2430                              LeuProTyrGlySerLeuArgAspTyrLeuGlnLysHisLysGlu                                  800805810                                                                      CGGATAGATCACAAAAAACTTCTTCAATACACATCTCAGATATGC2475                              ArgIleAspHisLysLysLeuLeuGlnTyrThrSerGlnIleCys                                  815820825                                                                      AAGGGCATGGAATATCTTGGTACAAAAAGGTATATCCACAGGGAC2520                              LysGlyMetGluTyrLeuGlyThrLysArgTyrIleHisArgAsp                                  830835840                                                                      CTGGCAACAAGGAACATATTGGTGGAAAATGAGAACAGGGTTAAA2565                              LeuAlaThrArgAsnIleLeuValGluAsnGluAsnArgValLys                                  845850855                                                                      ATAGGAGACTTCGGATTAACCAAAGTCTTGCCGCAGGACAAAGAA2610                              IleGlyAspPheGlyLeuThrLysValLeuProGlnAspLysGlu                                  860865870                                                                      TACTACAAAGTAAAGGAGCCAGGGGAAAGCCCCATATTCTGGTAC2655                              TyrTyrLysValLysGluProGlyGluSerProIlePheTrpTyr                                  875880885                                                                      GCACCTGAATCCTTGACGGAGAGCAAGTTTTCTGTGGCCTCAGAT2700                              AlaProGluSerLeuThrGluSerLysPheSerValAlaSerAsp                                  890895900                                                                      GTGTGGAGCTTTGGAGTGGTTCTATACGAACTTTTCACATACATC2745                              ValTrpSerPheGlyValValLeuTyrGluLeuPheThrTyrIle                                  905910915                                                                      GAGAAGAGTAAAAGTCCACCCGTGGAATTTATGCGAATGATTGGC2790                              GluLysSerLysSerProProValGluPheMetArgMetIleGly                                  920925930                                                                      AATGATAAACAAGGGCAAATGATTGTGTTCCATTTGATAGAGCTA2835                              AsnAspLysGlnGlyGlnMetIleValPheHisLeuIleGluLeu                                  935940945                                                                      CTGAAGAGCAACGGAAGATTGCCAAGGCCAGAAGGATGCCCAGAT2880                              LeuLysSerAsnGlyArgLeuProArgProGluGlyCysProAsp                                  950955960                                                                      GAGATTTATGTGATCATGACAGAGTGCTGGAACAACAATGTGAGC2925                              GluIleTyrValIleMetThrGluCysTrpAsnAsnAsnValSer                                  965970975                                                                      CAGCGTCCCTCCTTCAGGGACCTTTCCTTCGGGTGGATCAAATCC2970                              GlnArgProSerPheArgAspLeuSerPheGlyTrpIleLysSer                                  980985990                                                                      GGGACAGTATAGCTGCGTGAAAGAGATGGCCTTACTCAGAGACCAAGCA3019                          GlyThrVal                                                                      GACTTCCAGAACCAGAACAAAGCTCTGTAGCCTTGTGTCTACACATCCTT3069                         ATCATGACGCTAGCTAGGCAGAAAGAAAACTGTGACGCCGTCTGCTCAAA3119                         AGCTTTGGAAAACGCCGTGCAGGTTTGTTTCATCACCATCTGTAAAAACC3169                         ACTGCTCAAGTCTGGCAGCATGCTTGTGGGCTGATGCATGGAGCTCACCA3219                         CAGAGTCTCTGCATCTCCTCTGACAGAAGAAGAAAAATAGACAATTTTCA3269                         ACTCACTTTTTTGAGAAATGGAAAAAAATTATAATGTAAATTTTTCAGTG3319                         TAGGAAATACACAGAACATACATGTACAGTTTTTACCACGTGGAGTGTAT3369                         AATACTTTGGCCTCTTGTGTGATTTACATGAGGGCTGATGTTTGTTAATG3419                         TTTTCTAATTTTTCCATAGGTGATCTATAATAACTTCATGATACAAATTA3469                         AAATGCTCAGAAAATTAAAAAAAAAA3495                                                 (2) INFORMATION FOR SEQ ID NO:3:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 6 amino acid residues                                              (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (ix) FEATURE:                                                                  (D) OTHER INFORMATION: Xaa in positions 2, 4 and 5 is                          unknown.                                                                       (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:                                       GlyXaaGlyXaaXaaGly                                                             (2) INFORMATION FOR SEQ ID NO:4:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 16 amino acid residues                                             (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:                                       ThrSerPheGlnAsnLeuIleGluCysPheGluAlaLeuLeuLysCys                               51015                                                                          (2) INFORMATION FOR SEQ ID NO:5:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 21 base pairs                                                      (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:                                       TACACCTTTAAATATTTTTGT21                                                        (2) INFORMATION FOR SEQ ID NO:6:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 17 base pairs                                                      (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:                                       CTCGAGTCGACGAATTC17                                                            (2) INFORMATION FOR SEQ ID NO:7:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 20 base pairs                                                      (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:                                       CTTGCTTAATACTGACATCA20                                                         (2) INFORMATION FOR SEQ ID NO:8:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 20 base pairs                                                      (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:                                       CTTGCTTAATACTGACATCA20                                                         (2) INFORMATION FOR SEQ ID NO:9:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 9 base pairs                                                       (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:                                       TAAATGCAG9                                                                     (2) INFORMATION FOR SEQ ID NO:10:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 9 base pairs                                                       (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:                                      GCCATGGCT9                                                                     (2) INFORMATION FOR SEQ ID NO:11:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 8 amino acid residues                                              (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:                                      GlyLeuTyrValLeuArgTrpSer                                                       8                                                                              (2) INFORMATION FOR SEQ ID NO:12:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 7 amino acid residues                                              (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:                                      ValAspGlyTyrPheArgIle                                                          5                                                                              (2) INFORMATION FOR SEQ ID NO: 13:                                             (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 47 amino acids                                                     (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:                                      LysIleGlyGluGlyThrTyrGlyValValTyrLysGlyArgHis                                  51015                                                                          LysThrThrGlyGlnValValAlaMetLysLysIleArgLeuGlu                                  202530                                                                         SerGluGluGluGlyValProSerThrAlaIleArgGluIleSer                                  354045                                                                         LeuLeu                                                                         (2) INFORMATION FOR SEQ ID NO: 14:                                             (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 82 amino acids                                                     (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:                                      ValPheCysHisSerArgArgValLeuHisArgAspLeuLysPro                                  51015                                                                          GlnAsnLeuLeuIleAspAspLysGlyThrIleLysLeuAlaAsp                                  202530                                                                         PheGlyLeuAlaArgAlaPheGlyIleProIleArgValTyrThr                                  354045                                                                         HisGluValValThrLeuTrpTyrArgSerProGluValLeuLeu                                  505560                                                                         GlySerAlaArgTyrSerThrProValAspIleTrpSerIleGly                                  657075                                                                         ThrIlePheAlaGluLeuAla                                                          80                                                                             (2) INFORMATION FOR SEQ ID NO: 15:                                             (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 30 amino acids                                                     (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:                                      LeuAlaSerHisHisValLysAsnLeuAspGluAsnGlyLeuAsp                                  51015                                                                          LeuLeuSerLysMetLeuIleTyrAspProAlaLysArgIleSer                                  202530                                                                         (2) INFORMATION FOR SEQ ID NO: 16:                                             (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 601 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:                                      ValPheHisLysIleArgAsnGluAspLeuIlePheAsnGluSer                                  51015                                                                          LeuGlyGlnGlyThrPheThrLysIlePheLysGlyValArgArg                                  202530                                                                         GluValGlyAspTyrGlyGlnLeuHisGluThrGluValLeuLeu                                  354045                                                                         LysValLeuAspLysAlaHisArgAsnTyrSerGluSerPhePhe                                  505560                                                                         GluAlaAlaSerMetMetSerGlnLeuSerHisLysHisLeuVal                                  657075                                                                         LeuAsnTyrGlyValCysValCysGlyGluGluAsnIleLeuVal                                  808590                                                                         GlnGluPheValLysPheGlySerLeuAspThrTyrLeuLysLys                                  95100105                                                                       AsnLysAsnSerIleAsnIleLeuTrpLysLeuGlyValAlaLys                                  110115120                                                                      GlnLeuAlaTrpAlaMetHisPheLeuGluGluLysSerLeuIle                                  125130135                                                                      HisGlyAsnValCysAlaLysAsnIleLeuLeuIleArgGluGlu                                  140145150                                                                      AspArgArgThrGlyAsnProProPheIleLysLeuSerAspPro                                  155160165                                                                      GlyIleSerIleThrValLeuProLysAspIleSerSerCysCys                                  170175180                                                                      PheGlnValLeuGlnGluArgIleProTrpValProProGluCys                                  185190195                                                                      IleGluAsnProLysAsnLeuThrLeuAlaThrAspLysTrpSer                                  200205210                                                                      PheGlyThrThrLeuTrpGluIleCysSerGlyGlyAspLysPro                                  215220225                                                                      LeuSerAlaLeuAspSerGlnArgLysLeuGlnPheTyrGluAsp                                  230235240                                                                      LysHisGlnLeuProAlaProLysTrpThrGluLeuAlaAsnLeu                                  245250255                                                                      IleAsnAsnCysMetAspTyrGluProAspPheArgProAlaPhe                                  260265270                                                                      ArgAlaValIleArgAspLeuAsnSerLeuPheThrProAspTyr                                  275280285                                                                      GluLeuLeuThrGluAsnAspMetLeuProAsnMetArgIleGly                                  290295300                                                                      AlaLeuGlyPheSerGlyAlaPheGluAspArgAspProThrGln                                  305310315                                                                      PheGluGluArgHisLeuLysPheLeuGlnGlnLeuGlyLysGly                                  320325330                                                                      AsnPheGlySerValGluMetCysArgTyrAspProLeuGlnAsp                                  335340345                                                                      AsnThrGlyGluValValAlaValLysLysLeuGlnHisSerThr                                  350355360                                                                      GluGluHisLeuArgAspPheGluArgGluIleGluIleLeuLys                                  365370375                                                                      SerLeuGlnHisAspAsnIleValLysTyrLysGlyValCysTyr                                  380385390                                                                      SerAlaGlyArgArgAsnLeuArgLeuIleMetGluTyrLeuPro                                  395400405                                                                      TyrGlySerLeuArgAspTyrLeuGlnLysHisLysGluArgIle                                  410415420                                                                      AspHisLysLysLeuLeuGlnTyrThrSerGlnIleCysLysGly                                  425430435                                                                      MetGluTyrLeuGlyThrLysArgTyrIleHisArgAspLeuAla                                  440445450                                                                      ThrArgAsnIleLeuValGluAsnGluAsnArgValLysIleGly                                  455460465                                                                      AspPheGlyLeuThrLysValLeuProGlnAspLysGluTyrTyr                                  470475480                                                                      LysValLysGluProGlyGluSerProIlePheTrpTyrAlaPro                                  485490495                                                                      GluSerLeuThrGluSerLysPheSerValAlaSerAspValTrp                                  500505510                                                                      SerPheGlyValValLeuTyrGluLeuPheThrTyrIleGluLys                                  515520525                                                                      SerLysSerProProValGluPheMetArgMetIleGlyAsnAsp                                  530535540                                                                      LysGlnGlyGlnMetIleValPheHisLeuIleGluLeuLeuLys                                  545550555                                                                      SerAsnGlyArgLeuProArgProGluGlyCysProAspGluIle                                  560565570                                                                      TyrValIleMetThrGluCysTrpAsnAsnAsnValSerGlnArg                                  575580585                                                                      ProSerPheArgAspLeuSerPheGlyTrpIleLysSerGlyThr                                  590595600                                                                      Val                                                                            (2) INFORMATION FOR SEQ ID NO: 17:                                             (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 581 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:                                      SerPheAspArgIleLeuLysLysAspLeuValGlnGlyGluHis                                  51015                                                                          LeuGlyArgGlyThrArgThrHisIleTyrSerGlyThrLeuMet                                  202530                                                                         AspTyrLysAspAspGluGlyThrSerGluGluLysLysIleLys                                  354045                                                                         ValIleLeuLysValLeuAspProSerHisArgAspIleSerLeu                                  505560                                                                         AlaPhePheGluAlaAlaSerMetMetArgGlnValSerHisLys                                  657075                                                                         HisIleValTyrLeuTyrGlyValCysValArgAspValGluAsn                                  808590                                                                         IleMetValGluGluPheValGluGlyGlyProLeuAspLeuPhe                                  95100105                                                                       MetHisArgLysSerAspValLeuThrThrProTrpLysPheLys                                  110115120                                                                      ValAlaLysGlnLeuAlaSerAlaLeuSerTyrLeuGluAspLys                                  125130135                                                                      AspLeuValHisGlyAsnValCysThrLysAsnLeuLeuLeuAla                                  140145150                                                                      ArgGluGlyIleAspSerGluCysGlyProPheIleLysLeuSer                                  155160165                                                                      AspProGlyIleProIleThrValLeuSerArgGlnGluCysIle                                  170175180                                                                      GluArgIleProTrpIleAlaProGluCysValGluAspSerLys                                  185190195                                                                      AsnLeuSerValAlaAlaAspLysTrpSerPheGlyThrThrLeu                                  200205210                                                                      TrpGluIleCysTyrAsnGlyGluIleProLeuLysAspLysThr                                  215220225                                                                      LeuIleGluLysGluArgPheTyrGluSerArgCysArgProVal                                  230235240                                                                      ThrProSerCysLysGluLeuAlaAspLeuMetThrArgCysMet                                  245250255                                                                      AsnTyrAspProAsnGlnArgProPhePheArgAlaIleMetArg                                  260265270                                                                      AspIleAsnLysLeuGluGluGlnAsnProAspIleValSerArg                                  275280285                                                                      LysLysAsnGlnProThrGluValAspProThrHisPheThrLys                                  290295300                                                                      ArgPheLeuLysArgIleArgAspLeuGlyGluGlyHisPheGly                                  305310315                                                                      LysValGluLeuCysArgTyrAspProGluAspAsnThrGlyGlu                                  320325330                                                                      GlnValAlaValLysSerLeuLysProGluSerGlyGlyAsnHis                                  335340345                                                                      IleAlaAspLeuLysLysGluIleGluIleLeuArgAsnLeuTyr                                  350355360                                                                      HisGluAsnIleValLysTyrLysGlyIleCysThrGluAspGly                                  365370375                                                                      GlyAsnGlyIleLysLeuIleMetGluPheLeuProSerGlySer                                  380385390                                                                      LeuLysGluTyrLeuProLysAsnLysAsnLysIleAsnLeuLys                                  395400405                                                                      GlnGlnLeuLysTyrAlaValGlnIleCysLysGlyMetAspTyr                                  410415420                                                                      LeuGlySerArgGlnTyrValHisArgAspLeuAlaAlaArgAsn                                  425430435                                                                      ValLeuValGluSerGluHisGlnValLysIleGlyAspPheGly                                  440445450                                                                      LeuThrLysAlaIleGluThrAspLysGluTyrTyrThrValLys                                  455460465                                                                      AspAspArgAspSerProValPheTrpTyrAlaProGluCysLeu                                  470475480                                                                      MetGlnSerLysPheTyrIleAlaSerAspValTrpSerPheGly                                  485490495                                                                      ValThrLeuHisGluLeuLeuThrTyrCysAspSerAspSerSer                                  500505510                                                                      ProMetAlaLeuPheLeuLysMetIleGlyProThrHisGlyGln                                  515520525                                                                      MetThrValThrArgLeuValAsnThrLeuLysGluGlyLysArg                                  530535540                                                                      LeuProCysProProAsnCysProAspGluValTyrGlnLeuMet                                  545550555                                                                      ArgLysCysTrpGluPheGlnProSerAsnArgThrSerPheGln                                  560565570                                                                      AsnLeuIleGluGlyPheGluAlaLeuLeuLys                                              575580                                                                         (2) INFORMATION FOR SEQ ID NO: 18:                                             (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 1132 amino acids                                                   (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:                                      MetGlnTyrLeuAsnIleLysGluAspCysAsnAlaMetAlaPhe                                  51015                                                                          CysAlaLysMetArgSerSerLysLysThrGluValAsnLeuGlu                                  202530                                                                         AlaProGluProGlyValGluValIlePheTyrLeuSerAspArg                                  354045                                                                         GluProLeuArgLeuGlySerGlyGluTyrThrAlaGluGluLeu                                  505560                                                                         CysIleArgAlaAlaGlnAlaCysArgIleSerProLeuCysHis                                  657075                                                                         AsnLeuPheAlaLeuTyrAspGluAsnThrLysLeuTrpTyrAla                                  808590                                                                         ProAsnArgThrIleThrValAspAspLysMetSerLeuArgLeu                                  95100105                                                                       HisTyrArgMetArgPheTyrPheThrAsnTrpHisGlyThrAsn                                  110115120                                                                      AspAsnGluGlnSerValTrpArgHisSerProLysLysGlnLys                                  125130135                                                                      AsnGlyTyrGluLysLysLysIleProAspAlaThrProLeuLeu                                  140145150                                                                      AspAlaSerSerLeuGluTyrLeuPheAlaGlnGlyGlnTyrAsp                                  155160165                                                                      LeuValLysCysLeuAlaProIleArgAspProLysThrGluGln                                  170175180                                                                      AspGlyHisAspIleGluAsnGluCysLeuGlyMetAlaValLeu                                  185190195                                                                      AlaIleSerHisTyrAlaMetMetLysLysMetGlnLeuProGlu                                  200205210                                                                      LeuProLysAspIleSerTyrLysArgTyrIleProGluThrLeu                                  215220225                                                                      AsnLysSerIleArgGlnArgAsnLeuLeuThrArgMetArgIle                                  230235240                                                                      AsnAsnValPheLysAspPheLeuLysGluPheAsnAsnLysThr                                  245250255                                                                      IleCysAspSerSerValSerThrHisAspLeuLysValLysTyr                                  260265270                                                                      LeuAlaThrLeuGluThrLeuThrLysHisTyrGlyAlaGluIle                                  275280285                                                                      PheGluThrSerMetLeuLeuIleSerSerGluAsnGluMetAsn                                  290295300                                                                      TrpPheHisSerAsnAspGlyGlyAsnValLeuTyrTyrGluVal                                  305310315                                                                      MetValThrGlyAsnLeuGlyIleGlnTrpArgHisLysProAsn                                  320325330                                                                      ValValSerValGluLysGluLysAsnLysLeuLysArgLysLys                                  335340345                                                                      LeuGluAsnLysAspLysLysAspGluGluLysAsnLysIleArg                                  350355360                                                                      GluGluTrpAsnAsnPheSerPhePheProGluIleThrHisIle                                  365370375                                                                      ValIleLysGluSerValValSerIleAsnLysGlnAspAsnLys                                  380385390                                                                      LysMetGluLeuLysLeuSerSerHisGluGluAlaLeuSerPhe                                  395400405                                                                      ValSerLeuValAspGlyTyrPheArgLeuThrAlaAspAlaHis                                  410415420                                                                      HisTyrLeuCysThrAspValAlaProProLeuIleValHisAsn                                  425430435                                                                      IleGlnAsnGlyCysHisGlyProIleCysGluTyrAlaIleAsn                                  440445450                                                                      LysLeuArgGlnGluGlySerGluGluGlyMetTyrValLeuArg                                  455460465                                                                      TrpSerCysThrAspPheAspAsnIleLeuMetThrValThrCys                                  470475480                                                                      PheGluLysSerGluGlnValGlnGlyAlaGlnLysGlnPheLys                                  485490495                                                                      AsnPheGlnIleGluValGlnLysGlyArgTyrSerLeuHisGly                                  500505510                                                                      SerAspArgSerPheProSerLeuGlyAspLeuMetSerHisLeu                                  515520525                                                                      LysLysGlnIleLeuArgThrAspAsnIleSerPheMetLeuLys                                  530535540                                                                      ArgCysCysGlnProLysProArgGluIleSerAsnLeuLeuVal                                  545550555                                                                      AlaThrLysLysAlaGlnGluTrpGlnProValTyrProMetSer                                  560565570                                                                      GlnLeuSerPheAspArgIleLeuLysLysAspLeuValGlnGly                                  575580585                                                                      GluHisLeuGlyArgGlyThrArgThrHisIleTyrSerGlyThr                                  590595600                                                                      LeuMetAspTyrLysAspAspGluGlyThrSerGluGluLysLys                                  605610615                                                                      IleLysValIleLeuLysValLeuAspProSerHisArgAspIle                                  620625630                                                                      SerLeuAlaPhePheGluAlaAlaSerMetMetArgGlnValSer                                  635640645                                                                      HisLysHisIleValTyrLeuTyrGlyValCysValArgAspVal                                  650655660                                                                      GluAsnIleMetValGluGluPheValGluGlyGlyProLeuAsp                                  665670675                                                                      LeuPheMetHisArgLysSerAspValLeuThrThrProTrpLys                                  680685690                                                                      PheLysValAlaLysGlnLeuAlaSerAlaLeuSerTyrLeuGlu                                  695700705                                                                      AspLysAspLeuValHisGlyAsnValCysThrLysAsnLeuLeu                                  710715720                                                                      LeuAlaArgGluGlyIleAspSerGluCysGlyProPheIleLys                                  725730735                                                                      LeuSerAspProGlyIleProIleThrValLeuSerArgGlnGlu                                  740745750                                                                      CysIleGluArgIleProTrpIleAlaProGluCysValGluAsp                                  755760765                                                                      SerLysAsnLeuSerValAlaAlaAspLysTrpSerPheGlyThr                                  770775780                                                                      ThrLeuTrpGluIleCysTyrAsnGlyGluIleProLeuLysAsp                                  785790795                                                                      LysThrLeuIleGluLysGluArgPheTyrGluSerArgCysArg                                  800805810                                                                      ProValThrProSerCysLysGluLeuAlaAspLeuMetThrArg                                  815820825                                                                      CysMetAsnTyrAspProAsnGlnArgProPhePheArgAlaIle                                  830835840                                                                      MetArgAspIleAsnLysLeuGluGluGlnAsnProAspIleVal                                  845850855                                                                      SerArgLysLysAsnGlnProThrGluValAspProThrHisPhe                                  860865870                                                                      LysArgPheLeuLysArgIleArgAspLeuGlyGluGlyHisPhe                                  875880885                                                                      GlyLysValGluLeuCysArgTyrAspProGluAspAsnThrGly                                  890895900                                                                      GluGlnValAlaValLysSerLeuLysProGluSerGlyGlyAsn                                  905910915                                                                      HisIleAlaAspLeuLysLysGluIleGluIleLeuArgAsnLeu                                  920925930                                                                      TyrHisGluAsnIleValLysTyrLysGlyIleCysThrGluAsp                                  935940945                                                                      GlyGlyAsnGlyIleLysLeuIleMetGluPheLeuProSerGly                                  950955960                                                                      SerLeuLysGluTyrLeuProLysAsnLysAsnLysIleAsnLeu                                  965970975                                                                      LysGlnGlnLeuLysTyrAlaValGlnIleCysLysGlyMetAsp                                  980985990                                                                      TyrLeuGlySerArgGlnTyrValHisArgAspLeuAlaAlaArg                                  99510001005                                                                    AsnValLeuValGluSerGluHisGlnValLysIleGlyAspPhe                                  101010151020                                                                   GlyLeuThrLysAlaIleGluThrAspLysGluTyrTyrThrVal                                  102510301035                                                                   LysAspAspArgAspSerProValPheTrpTyrAlaProGluCys                                  104010451050                                                                   LeuMetGlnSerLysPheTyrIleAlaSerAspValTrpSerPhe                                  105510601065                                                                   GlyValThrLeuHisGluLeuLeuThrTyrCysAspSerAspSer                                  107010751080                                                                   SerProMetAlaLeuPheLeuLysMetIleGlyProThrHisGly                                  108510901095                                                                   GlnMetThrValThrArgLeuValAsnThrLeuLysGluGlyLys                                  110011051110                                                                   ArgLeuProCysProProAsnCysProAspGluValTyrGlnLeu                                  111511201125                                                                   MetArgLysCysTrpGluPhe                                                          1130                                                                           (2) INFORMATION FOR SEQ ID NO: 19:                                             (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 971 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:                                      LeuLeuAspAspPheValMetSerTyrLeuSerProGlnTrpArg                                  51015                                                                          HisAspPheValHisGlyTrpIleLysValProValThrHisGlu                                  202530                                                                         ThrGlnGluGluCysLeuGlyMetAlaValLeuAspMetMetArg                                  354045                                                                         IleAlaLysGluLysAspGlnThrProLeuAlaValTyrAsnSer                                  505560                                                                         ValSerTyrLysThrPheLeuProLysCysValArgAlaLysIle                                  657075                                                                         GlnAspTyrHisIleLeuThrArgLysArgIleArgTyrArgPhe                                  808590                                                                         ArgArgPheIleGlnGlnPheSerGlnCysLysAlaThrAlaArg                                  95100105                                                                       AsnLeuLysLeuLysTyrLeuIleAsnLeuGluThrLeuGlnSer                                  110115120                                                                      AlaPheTyrThrGluGlnPheGluValLysGluSerAlaArgGly                                  125130135                                                                      ProSerGlyGluGluIlePheAlaThrIleIleIleThrGlyAsn                                  140145150                                                                      GlyGlyIleGlnTrpSerArgGlyLysHisLysGluSerGluThr                                  155160165                                                                      LeuThrGluGlnAspLeuGlnLeuTyrCysAspPheProAspIle                                  170175180                                                                      IleAspValSerIleLysGlnAlaAsnGlnGluCysSerThrGlu                                  185190195                                                                      SerArgIleValThrValHisLysGlnAspGlyGluValLeuGlu                                  200205210                                                                      IleGluLeuSerSerLeuLysGluAlaLeuSerPheValSerLeu                                  215220225                                                                      IleAspGlyTyrTyrArgLeuThrAlaAspAlaHisHisTyrLeu                                  230235240                                                                      CysLysGluValAlaProProAlaValLeuGluAsnIleHisSer                                  245250255                                                                      AsnCysHisGlyProIleSerMetAspPheAlaIleSerLysLeu                                  260265270                                                                      LysLysAlaGlyAsnGlnThrGlyLeuTyrValLeuArgCysSer                                  275280285                                                                      ProLysAspPheAsnLysTyrPheLeuThrPheAlaValGluArg                                  290295300                                                                      GluAsnValIleGluTyrLysHisCysLeuIleThrLysAsnGlu                                  305310315                                                                      AsnGlyGluTyrAsnLeuSerGlyThrLysArgAsnPheSerSer                                  320325330                                                                      LeuLysAspLeuLeuAsnCysTyrGlnMetGluThrValArgSer                                  335340345                                                                      AspSerIleIlePheGlnPheThrLysCysCysProProLysPro                                  350355360                                                                      LysAspLysSerAsnLeuLeuValPheArgThrAsnGlyValSer                                  365370375                                                                      AspValGlnLeuSerProThrLeuGlnArgHisAsnAsnValAsn                                  380385390                                                                      GlnMetValPheHisLysIleArgAsnGluAspLeuIlePheAsn                                  395400405                                                                      GluSerLeuGlyGlnGlyThrPheThrLysIlePheLysGlyVal                                  410415420                                                                      ArgArgGluValGlyAspTyrGlyGlnLeuHisGluThrGluVal                                  425430435                                                                      LeuLeuLysValLeuAspLysAlaHisArgAsnTyrSerGluSer                                  440445450                                                                      PhePheGluAlaAlaSerMetMetSerGlnLeuSerHisLysHis                                  455460465                                                                      LeuValLeuAsnTyrGlyValCysValCysGlyGluGluAsnIle                                  470475480                                                                      LeuValGlnGluPheValLysPheGlySerLeuAspThrTyrLeu                                  485490495                                                                      LysLysAsnLysAsnSerIleAsnIleLeuTrpLysLeuGlyVal                                  500505510                                                                      AlaLysGlnLeuAlaTrpAlaMetHisPheLeuGluGluLysSer                                  515520525                                                                      LeuIleHisGlyAsnValCysAlaLysAsnIleLeuLeuIleArg                                  530535540                                                                      GluGluAspArgArgThrGlyAsnProPheIleLysLeuSerAsp                                  545550555                                                                      ProGlyIleSerIleThrValLeuProLysAspIleSerSerCys                                  560565570                                                                      CysPheGlnValLeuGlnGluArgIleProTrpValProProGlu                                  575580585                                                                      CysIleGluAsnProLysAsnLeuThrLeuAlaThrAspLysTrp                                  590595600                                                                      SerPheGlyThrThrLeuTrpGluIleCysSerGlyGlyAspLys                                  605610615                                                                      ProLeuSerAlaLeuAspSerGlnArgLysLeuGlnPheTyrGlu                                  620625630                                                                      AspLysHisGlnLeuProAlaProLysTrpThrGluLeuAlaAsn                                  635640645                                                                      LeuIleAsnAsnCysMetAspTyrGluProAspPheArgProAla                                  650655660                                                                      PheArgAlaValIleArgAspLeuAsnSerLeuPheThrProAsp                                  665670675                                                                      TyrGluLeuLeuThrGluAsnAspMetLeuProAsnMetArgIle                                  680685690                                                                      GlyAlaLeuGlyPheSerGlyAlaPheGluAspArgAspProThr                                  695700705                                                                      GlnPheGluGluArgHisLeuLysPheLeuGlnGlnLeuGlyLys                                  710715720                                                                      GlyAsnPheGlySerValGluMetCysArgTyrAspProLeuGln                                  725730735                                                                      AspAsnThrGlyGluValValAlaValLysLysLeuGlnHisSer                                  740745750                                                                      ThrGluGluHisLeuArgAspPheGluArgGluIleGluIleLeu                                  755760765                                                                      LysSerLeuGlnHisAspAsnIleValLysTyrLysGlyValCys                                  770775780                                                                      TyrSerAlaGlyArgArgAsnLeuArgLeuIleMetGluTyrLeu                                  785790795                                                                      ProTyrGlySerLeuArgAspTyrLeuGlnLysHisLysGluArg                                  800805810                                                                      IleAspHisLysLysLeuLeuGlnTyrThrSerGlnIleCysLys                                  815820825                                                                      GlyMetGluTyrLeuGlyThrLysArgTyrIleHisArgAspLeu                                  830835840                                                                      AlaThrArgAsnIleLeuValGluAsnGluAsnArgValLysIle                                  845850855                                                                      GlyAspPheGlyLeuThrLysValLeuProGlnAspLysGluTyr                                  860865870                                                                      TyrLysValLysGluProGlyGluSerProIlePheTrpTyrAla                                  875880885                                                                      ProGluSerLeuThrGluSerLysPheSerValAlaSerAspVal                                  890895900                                                                      TrpSerPheGlyValValLeuTyrGluLeuPheThrTyrIleGlu                                  905910915                                                                      LysSerLysSerProProValGluPheMetArgMetIleGlyAsn                                  920925930                                                                      AspLysGlnGlyGlnMetIleValPheHisLeuIleGluLeuLeu                                  935940945                                                                      LysSerAsnGlyArgLeuProArgProGluGlyCysProAspGlu                                  950955960                                                                      IleTyrValIleMetThrGluCysTrpAsnAsn                                              965970                                                                         (2) INFORMATION FOR SEQ ID NO:20:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 1184 amino acids                                                   (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:                                       MetProLeuArgHisTrpGlyMetAlaArgGlySerLysProVal                                  51015                                                                          GlyAspGlyAlaGlnProMetAlaAlaMetGlyGlyLeuLysVal                                  202530                                                                         LeuLeuHisTrpAlaGlyProGlyGlyGlyGluProTrpValThr                                  354045                                                                         PheSerGluSerSerLeuIleAlaGluGluValCysIleHisIle                                  505560                                                                         AlaHisLysValGlyIleThrProProCysPheAsnLeuPheAla                                  657075                                                                         LeuPheAspAlaGlnAlaGlnValTrpLeuProProAsnHisIle                                  808590                                                                         LeuGluIleProArgAspAlaSerLeuMetLeuTyrPheArgIle                                  95100105                                                                       ArgPheTyrPheArgAsnTrpHisGlyMetAsnProArgGluPro                                  110115120                                                                      AlaGlyTyrArgCysGlyProProGlyThrGluAlaSerSerAsp                                  125130135                                                                      GlnThrAlaGlnGlyMetGlnLeuLeuAspProAlaSerPheGlu                                  140145150                                                                      TyrLeuPheGluGlnGlyLysHisGluPheGluAsnAspValAla                                  155160165                                                                      SerLeuTrpGluLeuSerThrGluGluGluIleHisHisPheLys                                  170175180                                                                      AsnGluSerLeuGlyMetAlaPheLeuHisLeuCysHisLeuAla                                  185190195                                                                      LeuArgHisGlyIleProLeuGluGluValAlaLysLysThrSer                                  200205210                                                                      PheLysAspCysIleProArgSerPheArgArgHisIleArgGln                                  215220225                                                                      HisSerAlaLeuThrArgLeuArgLeuArgAsnValPheArgArg                                  230235240                                                                      PheLeuArgAspPheGlnProGlyArgLeuSerGlnGlnMetVal                                  245250255                                                                      MetValLysTyrLeuAlaThrLeuGluArgLeuAlaProArgPhe                                  260265270                                                                      GlyThrGluArgValProValCysHisLeuArgLeuLeuAlaGln                                  275280285                                                                      AlaGluGlyGluProCysTyrIleArgAspSerGlyValAlaPro                                  290295300                                                                      ThrAspProGlyProGluSerAlaAlaGlyProProThrHisGlu                                  305310315                                                                      ValLeuValThrGlyThrGlyGlyIleGlnTrpTrpProValGlu                                  320325330                                                                      GluGluValAsnLysGluGluGlySerSerGlySerSerAlaArg                                  335340345                                                                      AsnProGlnAlaSerLeuPheGlyLysLysAlaLysAlaHisLys                                  350355360                                                                      AlaPheGlyGlnProAlaAspArgProArgGluProLeuTrpAla                                  365370375                                                                      TyrPheCysAspIleThrHisValValLeuLysGluHisCysVal                                  380385390                                                                      SerIleHisArgGlnAspAsnLysCysLeuGluLeuSerLeuPro                                  395400405                                                                      SerArgAlaAlaAlaLeuSerPheGluSerLeuValAspGlyTyr                                  410415420                                                                      PheArgLeuThrAlaAspSerSerHisTyrLeuCysHisGluVal                                  425430435                                                                      AlaProProArgLeuValMetSerIleArgAspGlyIleHisGly                                  440445450                                                                      ProLeuLeuGluProPheValGlnGlnAlaLysLeuArgProLeu                                  455460465                                                                      GluAspGlyLeuTyrLeuIleHisTrpSerThrSerHisProTyr                                  470475480                                                                      ArgLeuIleLeuThrValAlaGlnArgSerGlnAlaProAspGly                                  485490495                                                                      MetGlnSerLeuArgLeuArgLysPheProIleGluGlnGlnAsp                                  500505510                                                                      GlyAlaPheValLeuGluGlyTrpGlyArgSerPheProSerVal                                  515520525                                                                      ArgGluLeuGlyAlaAlaLeuGlnGlyCysLeuLeuArgAlaGly                                  530535540                                                                      AspAspCysPheSerLeuArgArgCysCysLeuProGlnProGly                                  545550555                                                                      GluThrSerAsnLeuIleIleMetArgGlyAlaArgAlaSerPro                                  560565570                                                                      ArgThrLeuAsnLeuSerGlnLeuSerPheHisArgValAspGln                                  575580585                                                                      LysGluIleThrGlnLeuSerHisLeuGlyGlnGlyThrArgThr                                  590595600                                                                      AsnValTyrGluGlyArgLeuArgValGluGlySerGlyAspPro                                  605610615                                                                      GluGluGlyLysMetAspAspGluAspProLeuValProGlyArg                                  620625630                                                                      AspArgGlyGlnGluLeuArgValValLeuLysValLeuAspPro                                  635640645                                                                      SerHisHisAspIleAlaLeuAlaPheTyrGluThrAlaSerLeu                                  650655660                                                                      MetSerGlnValSerHisThrHisLeuAlaPheValHisGlyVal                                  665670675                                                                      CysValArgGlyProGluAsnSerMetValThrGluTyrValGlu                                  680685690                                                                      HisGlyProLeuAspValTrpLeuArgArgGluArgGlyHisVal                                  695700705                                                                      ProMetAlaTrpLysMetValValAlaGlnGlnLeuAlaSerAla                                  710715720                                                                      LeuSerTyrLeuGluAsnLysAsnLeuValHisGlyAsnValCys                                  725730735                                                                      GlyArgAsnIleLeuLeuAlaArgLeuGlyLeuAlaGluGlyThr                                  740745750                                                                      SerProPheIleLysLeuSerAspProGlyCysGlyLeuGlyAla                                  755760765                                                                      LeuSerArgGluGluArgValGluArgIleProTrpLeuAlaPro                                  770775780                                                                      GluCysLeuProGlyGlyAlaAsnSerLeuSerThrAlaMetAsp                                  785790795                                                                      LysTrpGlyPheGlyAlaThrLeuLeuGluIleCysPheAspGly                                  800805810                                                                      GluAlaProLeuGlnSerArgSerProSerGluLysGluHisPhe                                  815820825                                                                      TyrGlnArgGlnHisArgLeuProGluProSerCysProGlnLeu                                  830835840                                                                      AlaThrLeuThrSerGlnCysLeuThrTyrGluProThrGlnArg                                  845850855                                                                      ProSerPheAlaThrIleLeuArgAspLeuThrArgValGlnPro                                  860865870                                                                      HisAsnLeuAlaAspValLeuThrValAsnArgAspSerProAla                                  875880885                                                                      ValGlyProThrThrPheHisLysArgTyrLeuLysLysIleArg                                  890895900                                                                      AspLeuGlyGluGlyHisPheGlyLysValSerLeuTyrCysTyr                                  905910915                                                                      AspProThrAsnAspGlyThrGlyGluMetValAlaValLysAla                                  920925930                                                                      LeuLysAlaAspCysGlyProGlnHisArgSerGlyTrpLysGln                                  935940945                                                                      GluIleAspIleLeuArgThrLeuTyrHisGluHisIleIleLys                                  950955960                                                                      TyrLysGlyCysCysGluAspGlnGlyGluLysSerLeuValMet                                  965970975                                                                      GluTyrValProLeuGlySerLeuArgAspTyrLeuProArgHis                                  980985990                                                                      SerIleGlyLeuAlaGlnLeuLeuLeuPheAlaGlnGlnIleCys                                  99510001005                                                                    GluGlyMetAlaTyrLeuHisAlaHisAspTyrIleHisArgAsp                                  101010151020                                                                   LeuAlaAlaArgAsnValLeuLeuAspAsnAspArgLeuValLys                                  102510301035                                                                   IleGlyAspPheGlyLeuAlaLysAlaValProGluGlyHisGlu                                  104010451050                                                                   TyrTyrArgValArgGluAspGlyAspSerProValPheTrpTyr                                  105510601065                                                                   AlaProGluCysLeuLysGluTyrAsnPheTyrTyrAlaSerAsp                                  107010751080                                                                   ValTrpSerPheGlyValThrLeuTyrGluLeuLeuThrHisCys                                  108510901095                                                                   AspSerSerGlnSerProProThrLysPheLeuGluLeuIleGly                                  110011051110                                                                   IleAlaGlnGlyGlnMetThrValLeuArgLeuThrGluLeuLeu                                  111511201125                                                                   GluArgGlyGluArgLeuProArgProAspLysCysProCysGlu                                  113011351140                                                                   ValTyrHisLeuMetLysAsnCysTrpGluThrGluAlaSerPhe                                  114511501155                                                                   ArgProThrPheGluAsnSerIleProIleLeuLysThrValHis                                  116011651170                                                                   GluLysTyrGlnGlyGlnAlaProSerValSerSerValCys                                     11751180                                                                       (2) INFORMATION FOR SEQ ID NO:21:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 92 amino acids                                                     (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:                                       TrpTyrHisGlyLysLeuAspArgThrIleAlaGluGluArgLeu                                  51015                                                                          ArgGlnAlaGlyLysSerGlySerTyrLeuIleArgGluSerAsp                                  202530                                                                         ArgArgProGlySerPheValLeuSerPheLeuSerGlnThrAsn                                  354045                                                                         ValValAsnHisPheArgIleIleAlaMetCysGlyAspTyrTyr                                  505560                                                                         IleGlyGlyArgArgPheSerSerLeuSerAspLeuIleGlyTyr                                  657075                                                                         TyrSerHisValSerCysLeuLeuLysGlyGluLysLeuLeuTyr                                  808590                                                                         ProVal                                                                         (2) INFORMATION FOR SEQ ID NO:22:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 91 amino acids                                                     (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:                                       TrpPheHisGlyLysIleSerLysGlnGluAlaTyrAsnLeuLeu                                  51015                                                                          MetThrValGlyGlnAlaCysSerPheLeuValArgProSerAsp                                  202530                                                                         AsnThrProGlyAspTyrSerLeuTyrPheArgThrSerGluAsn                                  354045                                                                         IleGlnArgPheLysIleCysProThrProAsnAsnGlnPheMet                                  505560                                                                         MetGlyGlyArgTyrTyrAsnSerIleGlyAspIleIleAspHis                                  657075                                                                         TyrArgLysGluGlnIleValGluGlyTyrTyrLeuLysGluPro                                  808590                                                                         Val                                                                            (2) INFORMATION FOR SEQ ID NO: 23:                                             (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 89 amino acids                                                     (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:                                      TrpTyrTrpGlyArgLeuSerArgGlyAspAlaValSerLeuLeu                                  51015                                                                          GlnGlyGlnArgHisGlyThrPheLeuValArgAspSerGlySer                                  202530                                                                         IleProGlyAspPheValLeuSerValSerGluSerSerArgVal                                  354045                                                                         SerHisTyrIleValAsnSerLeuGlyProAlaGlyGlyArgArg                                  505560                                                                         AlaGlyGlyGluPheAspSerLeuProSerLeuLeuGluPheTyr                                  657075                                                                         LysIleHisTyrLeuAspThrThrThrLeuIleGluProVal                                     8085                                                                           __________________________________________________________________________ 

I claim:
 1. A purified isolated nucleic acid molecule which codes for a human protein tyrosine kinase like molecule which has multiple protein kinase catalytic domains, but no SH2 domains, the complementary sequence of which hybridizes to the nucleotide sequence set forth in SEQ ID NO: 1 at a temperature of 65° C. 6XSSC, 1% SDS, with a final wash of 0.2xSSC, 0.1% SDS, at 65° C.
 2. The isolated nucleic acid molecule, consisting of the nucleotide sequence set forth in SEQ ID No:
 1. 3. The isolated nucleic acid molecule of claim 1, wherein said polypeptide comprises two kinase catalytic domains.
 4. The isolated nucleic acid molecule of claim 1, wherein said human protein tyrosine kinase like molecule has a molecular weight of form about 100,000 to about 200,000 daltons.
 5. The isolated nucleic acid molecule of claim 4, wherein said protein tyrosine kinase like molecule has a molecular weight of from about 120,000 to about 150,000 daltons. 